Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association

https://edoc.mdc-berlin.de/16566

Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9

Yumlu, S., Stumm, J., Bashir, S., Dreyer, A.K., Lisowski, P., Danner, E., Kühn, R.

This is the final version of the accepted manuscript. The original article has been published in final edited form in:

Methods 2017 MAY 15 ; 121-122: 29-44 2017 MAY 15 (first published online) doi: 10.1016/j.ymeth.2017.05.009

Publisher: Elsevier



Copyright © 2017 Elsevier Inc. All rights reserved. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy visit of this license, http://creativecommons.org/licenses/by-nc-nd/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

METHODS Issue: CRISPR-Cas systems for genome engineering and investigation

Article: Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9

Saniye Yumlu^{1, 2,*}, Jürgen Stumm^{1, 3,*}, Sanum Bashir^{1, 2}, Anne-Kathrin Dreyer^{1, 2}, Pawel Lisowski^{1, 4}, Eric Danner¹, Ralf Kühn^{1,2}

1) Max-Delbrück-Centrum für Molekulare Medizin, 13125 Berlin, Germany

2) Berlin Institute of Health, Kapelle-Ufer 2, 10117 Berlin, Germany

3) Helmholtz Center Munich, 85764 Neuherberg, Germany

4) Institute of Genetics and Animal Breeding, Polish Academy of Sciences, 05-552 Magdalenka, Poland

*) Equal contribution

Author contact information

Saniye Yumlu	Email: saniye.yumlu@mdc-berlin.de
Jürgen Stumm	Email: juergen.stumm@mdc-berlin.de
Sanam Bashir	Email: sanum.bashir@mdc-berlin.de
Pawel Lisowski	Email: pawel.lisowski@mdc-berlin.de
Anne-Kathrin Dreyer	Email: anne-kathrin.dreyer@mdc-berlin.de
Eric Danner	Email: eric.danner@mdc-berlin.de
Ralf Kühn	Email: ralf.kuehn@mdc-berlin.de

Manuscript correspondence

Keywords: pluripotent stem cells; gene editing; CRISPR; Cas9; Knockout; Knockin

1 Abstract

2 Human induced pluripotent stem cells (hiPSCs) represent an ideal in vitro platform to study human genetics and biology. The recent advent of programmable nucleases makes also the 3 4 human genome amenable to experimental genetics through either the correction of 5 mutations in patient-derived iPSC lines or the *de novo* introduction of mutations into otherwise healthy iPSCs. The production of specific and sometimes complex genotypes in 6 7 multiple cell lines requires efficient and streamlined gene editing technologies. In this article we provide protocols for gene editing in hiPSCs. We presently achieve high rates of gene 8 editing at up to three loci using a modified iCRISPR system. This system includes a 9 doxycycline inducible Cas9 and sgRNA/reporter plasmids for the enrichment of transfected 10 11 cells by fluorescence-activated cell sorting (FACS). Here we cover the selection of target 12 sites, vector construction, transfection, and isolation and genotyping of modified hiPSC 13 clones.

14

15 **1. Introduction**

Human induced pluripotent stem cells (hiPSCs) represent an ideal platform to study human genetics and biology *in vitro* [1,2]. Induced pluripotent stem cell lines can be established by reprogramming of somatic cells from any healthy or diseased individual [3], being able to embody the diversity of genotypes within the human population. Since hiPSCs are selfrenewing they can be propagated indefinitely in the pluripotent state but on demand differentiated into selected cell types such as neurons [4] or cardiomyocytes [5].

The strength of non-human model organisms is based on *in vivo* analysis and the availability 22 23 of reverse and forward genetic tools enabling functional genomics studies which unravel 24 genotype to phenotype connections, including disease related variants. The recent advent of programmable nucleases makes also the human genome amenable to experimental 25 genetics through either the correction of mutations in patient-derived iPSC lines or the de 26 novo introduction of mutations into otherwise healthy iPSCs [6,7]. Some heritable diseases 27 are strictly monogenetic, but observable phenotypes often depend on epistatic interaction 28 from multiple genes. An understanding of disease-specific epistasis will improve the 29 prediction of disease risks and elucidate disease mechanisms, e.g. distinguishing between 30 disease specifiers and modifiers [8,9]. In animal genetics genotypes and backgrounds can be 31 constructed and manipulated by breeding and backcrossing. In hiPSCs the genome is fixed, 32 33 so studies investigating the effects of human genetic diversity require the use of multiple cell 34 lines side-by-side.

The production of specific and sometimes complex genotypes in multiple cell lines requires efficient and streamlined gene editing technologies. We presently achieve high rates of gene editing at up to three loci using a modified iCRISPR system. This system includes a doxycycline inducible Cas9 and sgRNA/reporter plasmids for the enrichment of transfected cells by fluorescence-activated cell sorting (FACS). In this article we provide our protocols for gene editing in hiPSCs. Here we cover the selection of target sites, vector construction, transfection, and isolation and genotyping of modified hiPSC clones.

42

43 **1.1 Gene editing in hiPSCs**

44 Due to its efficiency and simplicity, the CRISPR/Cas9 system derived from Streptococcus 45 pyogenes [10] has become the preferred method for gene editing in mammalian cells [11-13]. CRISPR/Cas9 gene editing requires two basic components to achieve a DNA double-46 strand break (DSB) and subsequent gene editing: the Cas9 nuclease protein and a single 47 guide (sg)RNA to home the Cas9 nuclease. A DNA repair template is often additionally 48 provided to allow for homology directed repair (HDR). The first twenty nucleotides of sgRNAs 49 direct Cas9 to a specified complementary DNA target sequence via RNA-DNA hybridization. 50 The target sequence is always located upstream of an invariant protospacer adjacent motif 51 (PAM) sequence (NGG for SpCas9 from Streptococcus pyogenes). Upon correct 52 hybridization the Cas9 nuclease undergoes a conformational change and creates a DSB 53 located 3 bp upstream of the PAM site (Fig.1A, B) [14]. An advantage of the CRISPR/Cas9 54 55 system is that the Cas9 protein component is of universal use and new target sites can be easily targeted by addition of a new sgRNA sequence. The gene editing process follows 56 57 induction of DSBs where DNA repair pathways result in deletion, replacement or insertion of 58 sequences.

Two main DNA repair pathways exist in mammalian cells. In most instances DSBs 59 are repaired by the non-homologous end joining (NHEJ) pathway. NHEJ religates open DNA 60 ends using DNA ligase IV without using a repair template [15]. DSBs processed by the NHEJ 61 62 pathway frequently exhibit random small deletions and/or insertions of nucleotides (indels) (Fig. 1C). Within coding regions this results in frameshift (knockout) mutations in the majority 63 64 of cases. Alternative to NHEJ, DSBs can be repaired by HDR and requires a DNA molecule as repair template [16,17]. The natural endogenous use of HDR is for spontaneously 65 occurring DSBs. Cycling cells use the intact homologous region of the sister chromatid as 66 HDR template. To achieve precise sequence modifications at targeted DSBs, the HDR 67 pathway can be exploited to copy in a sequence of interest. This is done through the addition 68 of an artificial DNA template which mimics the sister chromatid by including homology 69

sequences located up- and downstream of the DSB and concurrently flanking a desired 70 sequence modification or insertion [18]. In the repair process gene conversion extends from 71 72 the template's homology regions into the heterologous sequence and also transfers the 73 modified region into the target sequence (knockin), enabling to introduce precise mutations 74 such as codon replacements or the insertion of reporter genes (Fig. 1C). Large sequence 75 insertions require the construction of plasmid-based gene targeting vectors which include 76 homology regions of > 1000 bp, whereas small sequence modifications can be introduced by using synthetic single-stranded DNA oligonucleotides (ssODN) with lengths of 100-150 nt. In 77 cycling cells both repair mechanisms work side by side, but most DSBs are repaired by the 78 79 prevailing NHEJ pathway whereas HDR occurs less frequently. In a population of transfected 80 hiPSCs cells the induction of DSBs leads to a variety of repaired alleles in individual cells. Therefore, single cell-derived subclones are established from this heterogeneous population 81 82 and genotyped for the presence of the desired mutant alleles. Isolated clones may harbor none, one or two differing mutant alleles and the occasional presence of non-clonal, mixed 83 colonies make precise genotyping an elaborate task to exclude errors. Efficient mutagenesis 84 protocols ensuring that gene editing occurs in the majority of treated cells are important to 85 avoid the time-intensive expansion and genotyping of large numbers of unedited wildtype 86 hiPSC clones. 87

88 Sequence deletions leading to gene inactivation (knockout) are commonly used for 89 modelling loss of function alleles. Sequence replacements aim for the introduction or 90 correction of disease-related point mutations. Sequence insertions are often used for the 91 generation of cell type-specific reporter alleles or the ectopic expression of therapeutic 92 proteins [6,7]. Furthermore, the multiplex gene editing approach enables the simultaneous 93 processing of several target genes by the combination of multiple sgRNAs [19].

Frequent gene editing applications include the correction of disease-related mutations 94 95 in patient-derived hiPSCs. The resulting engineered hiPSCs differ from the parental cells exclusively at the edited loci and are otherwise isogenic. Parallel differentiation of these 96 97 isogenic cell lines into disease-relevant cell-types provides the basis for the phenotypic analysis of cellular pathologies that are directly attributable to the genetic specific mutations 98 99 [2,20,21]. This reversion of disease-related phenotypes in cells derived from corrected 100 hiPSCs can serve as a paradigm for the feasibility of future cell based therapies. The CRISPR/Cas9 system can be used for modification of both copies of a target gene, or 101 restricted to induce changes only in alleles of interest by selective gene editing based on 102 haplotype-specific target sites [22-25]. 103

104 Gene editing in hiPSCs and other cells is now routinely performed using the

5

unmodified Cas9 nuclease. Effective use of Cas9 is constrained by the dependence on the 105 invariant PAM (NGG) motif and imperfect selectivity resulting in cleavage of unintended 106 107 genomic, `off-target' sequences that exhibit one or more mismatches to the desired on-target 108 site [26]. The level of off-target activity complicates Cas9 applications in cell-based disease 109 modeling as well as in clinical translation. The off-target cleavage can be minimized by 110 choosing target sequences showing minimal homology elsewhere in the genome. Whole 111 genome sequencing of hiPSCs does not observe off-target effects if highly specific gRNAs are used [27-29]. Additionally, the specificity of Cas9 has been improved by engineering 112 forms that destabilize the protein's interaction with the DNA. By decreasing the strength of 113 114 nonspecific DNA interactions through amino acid substitutions, the resulting Cas9 variants 115 are thermodynamically more dependent on perfect gRNA-DNA pairings, leading to decreases in off-target binding and cleavage. Two of these enzymes have been produced. 116 Zhang et al. [30] focused on residues that interact with the non-target DNA strand to 117 generate `enhanced' Cas9 (eCas9), whereas Joung [31] altered amino acids that contact the 118 DNA backbone on the target strand obtaining `high-fidelity' Cas9 (Cas9-HF). Using unbiased 119 genome-wide assays, both groups showed greatly reduced off-target activity below 120 detectable levels. The on-target cleavage of these variants is comparable (eCas9) or 121 approaches (Cas9-HF) the activity of wild-type Cas9. These modified nucleases are not yet 122 broadly used in hiPSCs but provide opportunities for future application. 123

- 124
- 125 126

- Figure 1 -

...

127 **1.2 Human induced pluripotent stem cell lines**

hiPSC lines can be established either from healthy individuals or from patients with inherited 128 or idiopathic diseases. Lines from healthy individuals either serve for studying human 129 developmental processes or as a framework for introduction of *de novo* or patient-derived 130 mutations into disease-associated genes. Patient-derived hiPSCs are used to study an 131 individual disease-prone genotype and the role of mutations identified in disease-related 132 genes. A large resource is the HipSci initiative [32] that offers more than 400 hiPSC lines 133 (www.hipsci.org) which are distributed via the ECACC (www.phe-culturecollections.org.uk). 134 Moreover, a variety of human stem cell lines is available from WiCell (www.wicell.org). 135 Despite the importance of allelic variants as part of the genetic background, it is a shortfall of 136 the present hiPSC research that genome sequences for most cell lines are not available, 137 except for the HipSci resource which offers whole exome sequencing (WES) for all and 138 whole genome sequencing (WGS) data for selected lines. Different hiPSC lines exhibit 139

individual properties such as susceptibility to various transfection treatments or culturetechniques approaches (see section 3.3).

142 **1.3 Gene editing approach**

The purpose of gene editing in a hiPSCs workflow may be the insertion of a specific 143 sequence from a HDR donor template, or the deletion of a genomic sequence. Templates for 144 HDR-mediated knockin may use donor vectors that include drug selection or fluorescent 145 marker genes enabling the efficient isolation of targeted colonies harboring stable vector 146 integrations [33,34]. In some cases, especially for gene therapeutic purposes, the marker 147 gene needs to be removed. This can be achieved by flanking the marker gene with 148 recombinase or transposase recognition sites that upon transient expression of recombinase 149 or transposase facilitate the removal of the marker gene. Alternatively, templates without 150 151 selection marker genes can be used for HDR such as ssODNs [35], providing that gene editing in the population of transfected cells is highly efficient. 152

153 Efficient methods would ideally allow the simultaneous introduction of knockout or knockin mutations into multiple genes (multiplex engineering) in different cell lines with 154 limited efforts. A first step into the direction of multiplexed gene editing is the genomic 155 integration of an inducible Cas9 expression vector into the AAVS1 locus. This allows for the 156 delivery of sgRNAs and HDR donors only, while yielding an increased gene targeting efficacy 157 in hiPSC. This approach was first described in hiPSCs as the doxycycline inducible iCRISPR 158 system which just requires the transfection of multiple sgRNAs and allows the knockout of up 159 to three genes in a single step [19]. Depending on the experimental setup, both classical 160 161 CRISPR/Cas9 and the iCRISPR system feature advantages and drawbacks. The former is 162 applicable to wildtype cells if no further genomic modifications are desired, e.g. experimental 163 (re-)engraftments. The latter was demonstrated to provide improved efficacy when applied to modify multiple loci, although prior cell line generation is required and a modified AAVS1 164 locus will remain if no strategies for final Cas9 gene removal are applied. 165

166 In this protocol we include two ways to achieve gene editing in hiPSCs. Both describe 167 detailed procedures on how to introduce CRISPR/Cas9-mediated, site-specific DSBs 168 followed by suggestions for analysis of resulting indel formations. These methods can further 169 provide a framework for HDR-mediated insertion.

The first approach, enables editing of single genes by transfection of a vector encoding Cas9 and sgRNA (cloned into pU6-(BbsI)sgRNA_CAG-Cas9-bpA_EF1-TagRFP or pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA, section 3.1.1) into unmodified hiPSC lines

(Workflow A, Fig. 2A). Included fluorescent Venus or RFP reporters enable subsequent 173 FACS isolation of transfected cells. The second approach focuses on multiplex gene editing 174 (Workflow B, Fig. 2B, 2C). This multiplexing protocol uses hiPSC lines with a doxycycline 175 176 inducible Cas9 expression system integrated in the AAVS1 locus. We currently use a 177 modified version of the iCRISPR system [19] which is available upon request. As described in section 3.3, these iCRISPR lines show a strong Cas9 expression when induced with 178 179 doxycycline. These cells are transfected with a small vector for the expression a fluorescent Venus reporter and of multiple sgRNAs (cloned into plasmid pU6-(BbsI)sgRNA CAG-Venus-180 bpA; section 3.1.1). This allows the fraction of successfully transfected hiPSCs expressing 181 182 sgRNAs and the reporter to be isolated by FACS. The sorted cells are then plated for the 183 establishment of single cell derived colonies (section 3.4).

Further improvements of this technology may be possible. We have found Cas9 to be heterogeneously expressed in iCRISPR cell lines after doxycycline induction. Therefore, we are further testing vectors for the induction of Cas9 and a second fluorescent reporter, enabling the two color FACS enrichment for cells expressing high levels of Cas9 and sgRNAs.

- Figure 2 -

189

- 190
- 191

192 **1.4 Guide RNA selection and project planning**

The selection of an appropriate RNA target site is determined by the specific aim of each 193 experiment. A frequent application of gene editing is the generation of knockout alleles by the 194 induction of indel formation at the DSB site by error-prone NHEJ repair causing frameshift 195 mutations and premature termination. To achieve gene disruption the sgRNA target site has 196 to be located in a protein coding exon that is included in all splice variants. Despite the 197 presence of a frameshift mutation in an mRNA, ribosomes may be able to reinitiate 198 199 translation at an ATG codon located downstream, generating a shortened protein [36]. 200 Therefore, coding regions should be analyzed for the likelihood of such illegitimate 201 translation events using the Netstart prediction e.q. server (http://www.cbs.dtu.dk/services/NetStart/) [37]. Besides forming knock-outs by indel 202 formation one can delete large sections of coding sequence or regulatory elements by cutting 203 with two sgRNAs. Deletions not necessarily have to affect a gene itself, but can involve 204 regulatory elements as well. Furthermore, chromosomal rearrangements, that are 205 duplications and inversions of regions up to more than 1 Mb, can be generated by the use of 206 two sgRNAs targeting sites in an appropriate distance [38,39]. 207

Once the genomic region of interest is identified a stretch of 150 – 250 bp can be 208 analyzed for the distribution and quality of Cas9 target sites. Due to their simple structure 209 210 target sites are found on average every 8–12 bp in the human genome and can be seen by visual inspection for NGG PAM motifs. However, the sequence composition of the 20 nt 211 212 target sequence (such as GC content) influences the nuclease activity of Cas9 at the target 213 site (on-target activity), as well as the probability that Cas9 cuts other related sites within the 214 genome (off-target activity). To analyze all sgRNAs for their on-target efficiency and off-target sites we prefer to use the CRISPOR website (http://crispor.tefor.net/) [40]. CRISPOR 215 provides scores for the specificity of sgRNAs as well as on-target efficiency using meta-216 217 analysis of all published activity ranking tools. Various studies suggest that off-target sites of 218 RNA-guided Cas9 nucleases can be variable in frequency, challenging to predict and it is not possible to predict how many mismatches can be tolerated [26]. Nevertheless, a careful 219 selection among the target sequences addressing a given genomic region of interest will 220 reduce the risk of creating off-target mutations. Therefore, we recommend to use only 221 222 sgRNAs showing the highest specificity scores and to save the information on potential offtarget sites for later PCR analysis (see section 3.5.8). 223

Genetic editing resulting in the generation of a knockin, being either an insertion or a regional 224 225 replacement, is achieved by HDR. To generate such a targeted sequence modification, the sgRNA target site should be located close (< 100 bp) to the position of the intended mutation 226 as the frequency of sequence conversion by HDR decreases with distance. Targeted 227 mutations by HDR are guided by repair templates, being either ssODNs or plasmid gene 228 229 targeting vectors [14,41]. ssODNs are convenient as they are synthetized for a reasonable price so that cloning work is not required. ssODNs used as HDR template contain a short 230 sequence modification (deletion, insertion or substitution) flanked by two homology 231 sequences. Many manufacturers of custom ssODNs offer lengths up to 150 nt or more, 232 233 enabling the insertion of sequences of up to ~50 nt. When using ssODNs we recommend the 234 selection of target sites that are less than 10 bp distant to the planned mutation. In the 235 standard design, as their length is limited, a desired mutation is located at the center of an 236 ssODN, resulting in similarly-sized homology regions (usually 40-60 nt each) that flank the desired mutation symmetrically on both sides. It is crucial to avoid the recognition and 237 recleaving of the recombined allele by Cas9 by the inclusion of one or more silent nucleotide 238 replacements to destroy the PAM recognition site. Silent mutations can be added to facilitate 239 later screening for successful recombination, e.g. by the introduction of a recognition site for 240 241 restriction enzymes for restriction fragment length polymorphism (RFLP).

Recent studies suggest that choice of the target strand and an asymmetric design of 242 ssODNs increase the knockin efficiency [42] and that phosphorothioate (PTO) modifications 243 improve stability and HDR efficacy [43]. However, it was not shown if these rules apply to 244 245 hiPSCs as well. We have performed a side by side evaluation of ssODNs with symmetric or 246 asymmetric structure with or without PTO modifications (Fig. 3). Analogously to Glaser et al. 247 [44], we used human iPS cells heterozygously expressing a CAG promoter driven EGFP 248 from the AAVS1 locus as a reporter system for HDR. The EGFP gene was targeted with a sgRNA to induce a DSB. By homologous recombination of donor templates that substitute 4 249 bp, the original green fluorescent EGFP is converted to blue fluorescent BFP and the PAM 250 251 sequence rendered non-functional, as previously reported [44]. Based on this assay, we 252 observed that in hiPSCs unmodified ssODNs without PTO modifications yield higher HDR rates compared to modified ones (Fig. 3). Furthermore, in contrast to HEK293 cells as 253 reported by Richardson et al. [42], a symmetric architecture of ssODNs resulted in higher 254 HDR efficiencies than an asymmetrical in hiPSCs (Fig. 3). However, the efficacy of 255 CRISPR/Cas9 mediated targeting of specific loci depends on the cell line subjected, the 256 localization of the locus within the chromatin architecture and the sequence itself. Therefore, 257 258 these observations cannot be generalized, but may vary in respect to the individual purpose.

259

- Figure 3-

For larger and more sophisticated modifications such as the insertion of cDNAs or 260 reporter cassettes, targeting vectors with long homology arms are required. Such vectors 261 include the insertion in between two regions homologous to sequences located up- and 262 downstream of the DSB. For the design and construction of gene targeting vectors, adhere to 263 protocols developed for gene targeting in mouse embryonic stem cells [45,46] with two 264 exceptions: a drug selection cassette is not required and the homology arms used are often 265 shorter (> 500 bp) that facilitates cloning by PCR or gene synthesis. For vector construction, 266 homology arms can be PCR-amplified from isogenic genomic DNA and ligated into a cloning 267 plasmid backbone. Alternatively, the insert can be generated by gene synthesis purchased 268 from a commercial provider. In the simplest configuration the selected Cas9 recognition 269 sequence should cover the region of the intended mutation, bridging the homology arms of 270 271 the targeting vector to prevent its cleaving by Cas9, being specific only to the wildtype 272 genomic DNA.

273

274 1.5 Workflow of CRISPR/Cas9 gene editing in hiPSCs

For designing a new experimental setup our workflow for gene editing and clonal isolation of 275 hiPSCs follows a generalized sequence, as shown in Figure 4: 1. Cloning of a suitable 276 277 sgRNA expression vector. Assuming usage of available combined vectors to express Cas9 278 and sgRNA (section 2., Vectors) 7 days are estimated for the procedure and quality control. 279 2. Transfection of fluorescent reporter vectors carrying sgRNAs and Cas9 (Workflow A) or - if using an inducible Cas9 harboring iPS cell line - transfection with fluorescent reporter vectors 280 281 carrying only sgRNAs (Workflow B) and if desired repair templates. 3. On day 9, 48 h post transfection, the successfully transfected cells are enriched by FACS sorting for the 282 fluorescent reporter. 4. The FACS sorted cells are then plated at low density. To achieve a 283 284 good viability in feeder-free conditions and to prevent spontaneous differentiation the cells 285 are cultivated for 7 days in 50 % of conditioned medium [47]. 5. The single cell derived colonies can be picked on around day 16, further cultured and split to two separate 286 cultivations each. 6. After expansion for 5 more days, one of the two cultivations is subjected 287 to analysis of gene editing events (Fig. 6, B1-B6). 7. The other cultivation is kept in culture 288 until establishment of the final cell line or preparation of cryopreserved stocks on day 28. 289

Following these workflows and picking 24 colonies for further processing should yield at least two positive clone on average. However, as CRISPR/Cas9-mediated gene editing depends on the targeted loci as well as on the cell line used efficacies may vary. To promote increased efficacy of gene editing, we suggest performing a second round of transfection and FACS enrichment, and optionally to co-transfect a vector encoding for Trex2, an endprocessing enzyme.

- 296
- 297
- 298

- Figure 4-

299 **2**. **Materials**

- 300 2.1 Vectors
- 301 Workflow A

302	- pU6-(<i>Bbsl</i>)sgRNA_	_CAG-Cas9-bpA_	_EF1-TagRFP	(Addgene ID	86987,
-----	-----------------------------	----------------	-------------	-------------	--------

303 www.addgene.org) or

- 304 -pU6-(*BbsI*)sgRNA_CAG-Cas9-venus-bpA (Addgene ID 86986)
- 305 Plasmids for the cloning of a single sgRNA into the BbsI site and separate the
- 306 expression of Cas9 and RFP or the expression of a Cas9-venus fusion protein.
- 307

308 Workflow B

309	- pU6-(<i>Bbsl</i>)sgRNA_CAG-venus-bpA (Addgene ID 86985)	
310	Plasmid for the cloning of single or multiple sgRNAs into the BbsI site and the	
311	expression of Venus.	
312		
313	Optional: Co-expression of Trex2 (pCAG-mTrex2-bpA; Addgene ID 86984) enhances inc	lel
314	formation.	
315		
316	2.2 Cloning sgRNAs	
317	1. Empty sgRNA cloning vectors (section 2.1)	
318	2. A pair of target specific sgRNA oligos with BbsI overhangs, e.g. MWG-Biotech	
319	3. Bbsl restriction enzyme, NEB, #R0539S	
320	4. Ascl restriction enzyme, NEB, #R0558S	
321	5. T4 Ligase, NEB, #M0202S	
322	6. PureYield™ Plasmid Miniprep System, Promega, #A1222	
323	7. Chemical competent <i>E. coli</i> DH5α, Thermo Fisher, #18265-017	
324	8. Carbenicillin, Sigma, #C3416	
325	9. LB medium and LB agar plates	
326	10. Agarose gel electrophoresis (setup and consumables)	
327		
328	2.3 General hiPS cell culture	
329	1. hiPS cell lines (e.g. HPSI0114i-kolf_2, www.hipsci.org or MIRJT7i-mND2-0,	
330	www.wicell.org)	
331	2. Essential 8 medium, Thermo Fisher Scientific, # A1517001	
332	3. Y-27632 (dihydrochloride), Biomol, # Cay10005583-5	
333	4. DPBS -/- (-Ca ²⁺ , -Mg ²⁺), Life Technologies, # 14190169	
334	5. Vitronectin (VTN-N) Recombinant Human, Life Technologies, # A14700	
335	6. Matrigel Matrix, Fisher Scientific, # 10162371	
336	7. DMEM/F-12 Hepes, Life Technologies, # 31330038	
337	8. Cell culture plates (e.g. Corning Costar 6-well plates, # CLS3516-50EA)	
338	9. Accutase solution, Sigma-Aldrich, # A6964	
339	10. Bambanker Serum Free Cell Freezing Medium, BioCat, # BB01-NP	
340	11. DMSO, Sigma-Aldrich, # D5879	
341	12. Doxycycline Hydrochloride, Sigma-Aldrich, # D9891	
342	13. Dissociation buffer: 0.18 % NaCl, 0.5 mM EDTA in DPBS (to 491.92 ml DPBS ad	d 5
343	ml of 0.5M EDTA pH 8.0 and 3.8 ml of 5M NaCl)	

344	14.	ReLeSR, Stemcell Technologies, # 05872
345		
346	2.4 Lip	oofection of hiPS cells
347	1.	Lipofectamine 3000 transfection kit, Life Technologies, # L3000001
348	2.	Opti-MEM I reduced serum medium, Gibco, # 31985062
349		
350	2.5 Ele	ectroporation of hiPS cells with the Neon system
351	1.	Neon Transfection system, Thermo Fisher Scientific, # MPK5000
352	2.	Neon transfection kit 100µl, Thermo Fisher Scientific, # MPK10025
353		
354	2.6 Ele	ectroporation of hiPS cells with the Gene Pulser system
355	1.	Gene Pulser Xcell Electroporation Systems, Bio-Rad, # 1652660
356	2.	Gene Pulser electroporation cuvette 0.4 cm, Bio-Rad, # 1652081
357		
358	2.7 FA	CS enrichment of transfected hiPS cells
359	1.	0.45 μm PTFE membrane filter, Millipore, # SLCR025NS
360	2.	FACS tubes with 35 μ m strainer cap, Falcon, # 352235
361	3.	Penicillin/Streptomycin (10,000 U/ml), Life Technologies, # 15140122
362	4.	Gentamicin (10 mg/mL), Life Technologies, # 15710049
363	5.	RevitaCell Supplement (100X), Life Technologies, # A26445-01
364	6.	Fluorescence activated cell sorter (e.g. BD FACSAria III, BD Biosciences)
365		
366	2.8 An	alyzing modifications
367	1.	Wizard Genomic DNA Purification Kit, Promega, # A1125
368	2.	Wizard DNA Clean-Up System, Promega, # A9282
369	3.	Herculase II Fusion DNA Polymerase Kit, Agilent, # 600679
370	4.	Q5 High-Fidelity DNA Polymerase, NEB, # M0491S
371	5.	dNTP Set, Thermo Fisher Scientific, # R0181
372	6.	Gene specific primers, e.g. MWG-Biotech
373	7.	Fluorescence labeled gene specific primers, e.g. MWG-Biotech
374	8.	Restriction enzymes, NEB
375	9.	Thermocycler, e.g. Eppendorf
376	10.	Agarose gel electrophoresis (setup and consumables)
377		
378		

- 379 **3. Methods**
- 380

381 3.1 Cloning of sgRNAs

This protocol recommends the usage of either plasmid pU6-(Bbs/)sgRNA CAG-Cas9-382 venus-bpA or pU6-(BbsI)sgRNA CAG-Cas9 EF1-TagRFP (Workflow A), encoding for 383 sgRNA and Cas9 and a fluorescent Venus or RFP reporter, or usage of pU6-384 (Bbsl)sgRNA CAG-venus-bpA, carrying a sgRNA-cassette and a fluorescent reporter only 385 (Workflow B). These vectors allow expression of the sgRNA by the human U6-promoter. This 386 promoter requires a "G" base at the transcription start site. Hence, it is recommended using 387 388 CRISPR/Cas9 target sites starting with a "G". Otherwise an additional "G" should be added 389 at the start of the sgRNA sequence. It should be noted that wildtype Cas9 is amenable to the inclusion of an extra "G" but other RNA guided nucleases are not (Cas9-HF/eCas9). All 390 three above mentioned plasmids together with their maps and sequences are deposited at 391 Addgene (www.addgene.org) which also provides a wide range of other vector systems for 392 Cas9 expression and sgRNA cloning. 393

394 395

396 3.1.1 Cloning of a single sgRNA

397 Annealing of sgRNA oligos

The sgRNA oligos can be cloned into the above mentioned vectors by *Bbsl* restriction enzyme overhangs, with N_1 - N_{20} as the selected Cas9 target sequence:

400

401	sgRNA-oligo-F	5' –CACC(G)N1NNNNNNNNNNNNNNNNNNNNNNN
-----	---------------	--------------------------------------

- 402 sgRNA-oligo-R 5' –AAACNNNNNNNNNNNNNNNNNNN(C) –3'
- 403
- 404 1. Resuspend oligos at 1 μ g/ μ l in 1x TE-buffer.
- 405 2. Combine in a microcentrifuge tube
- 406 1 μl oligo F (1 μg/μl)
- 407 1 μl oligo R (1 μg/μl)
- 408 98 µl 1x TE-buffer
- 409 3. Incubate 5 min at 98 °C in a heat block.
- 4. Switch off the heat block and cool down slowly to RT for 1-2 h.
- 411 5. Put the annealed oligos on ice or store at -20 °C.

412

413 Digestion of sgRNA expression vector

414	1.	Set up digestion reaction as following:
415		 X μl of the above mentioned vectors (5 μg)
416		- 2.5 µl <i>Bbsl</i> (store at -80 °C)
417		- 10 μl NEB2 buffer
418		 Fill up to 100 μl with nuclease free water
419	2.	Incubate at 37°C for 1 h.
420	3.	Inactivate the restriction enzyme for 20 min at 65 °C.
421	4.	Load the digested vector on a 0.9% agarose gel and extract the linearized vector
422		using a DNA gel extraction kit. Expected fragment sizes are: pU6-
423		(BbsI)sgRNA_CAG-Cas9-venus-bpA – 10.1 kb; pU6-(BbsI)sgRNA_CAG-Cas9-
424		bpA_EF1-RFP – 11.6 kb; pU6-(BbsI)sgRNA_CAG-venus-bpA – 6.0 kb.
425		
426	Ligation	on of sgRNA oligos
427	1.	Set up ligation in a microcentrifuge tube
428		- X μl linearized vectors (100 ng)
429		- 1.5 μl annealed oligos (1 μg/μl each)
430		- 1.5 μl fresh ligase buffer
431		- 1 μl T4 DNA Ligase
432		 Fill up to 15 µl with nuclease free water and incubate O/N at 16 °C.
433	Trans	formation
434	1.	Thaw chemically competent <i>E. coli</i> on ice slowly.
435	2.	Pipet the transformation reaction on ice
436		- 50 μl chemically competent DH5 alpha <i>E. coli</i>
437		- 5 μl of the ligation mix.
438	3.	Incubate 30 min on ice.
439	4.	Perform the heat shock in a water bath at 42 °C for 90 sec.
440	5.	Incubate 3 min on ice.
441	6.	Add 1 ml LB medium w/o antibiotics and incubate 30 min at 37°C at 200 rpm.
442	7.	Plate the transformation on LB-Agar plates 50 μ g/ml carbenicillin or ampicillin and
443		incubate O/N at 37°C.
444	The ne	ext day pick up to five colonies and inoculate 5 mL LB medium containing 50 μ g/ml
445	carber	nicillin or ampicillin. Incubate O/N at 37 °C at 200 rpm. Perform plasmid mini
446	prepar	ations and subject for Sanger sequencing to verify the correct sequence using primer
447	hU6-F	or: GAGGGCCTATTTCCCATG.

448 Optional: Redigestion of the ligated plasmid using the enzyme *Bbsl* improves the cloning

449 <u>efficacy.</u>

450

451

452 **3.1.2 Cloning of multiple sgRNAs**

To clone multiple sgRNA expression cassettes in pU6-(Bbs/)sgRNA CAG-venus-bpA via 453 Gibson assembly, the individual sgRNAs have to be cloned separately beforehand as 454 455 previously described in section 3.1.1. These single sgRNA plasmids serve as template for amplifying a specific sgRNA cassettes including overlapping ends for Gibson assembly. The 456 following protocol enables to assemble two or three sgRNA expression cassettes in one 457 458 vector. If it is intended to clone more than three sgRNAs in one vector primer pairs have to 459 be designed with appropriate assembly overhangs, according to manufacturer guidelines. Following primers can be used for cloning: 460

461

462 Gibson-pU6-A F CAGGAAACAGCTATGACCATGAGGGCCCCCTTCACCGAGGGCCTATTTC 463 Gibson-pU6-A_R CCGATGGCCAGGCCGATGCTGTGATCAAAAAAGCACCGACTCGG 464 Gibson-pU6-B F ACAGCATCGGCCTGGCCATCGGGCCCCCTTCACCGAGGGCCTATTTC 465 466 Gibson-pU6-B R CTTGGCCATCTCGTTGCTGAAGATCAAAAAAGCACCGACTCGG 467 Gibson-pU6-C F TTCAGCAACGAGATGGCCAAGGCCCCCTTCACCGAGGGCCTATTTC 468 469 Gibson-pU6-C R GTCAATAATCAATGTCGAATCCGGGATCAAAAAAGCACCGACTCGG 470 471 Use primer combinations A F/A R; B F/B R and C F/C R if three cassettes are desired to 472 be cloned and combinations A F/A R and B F/C R if it is desired to clone two sgRNA 473 cassettes. 474 Amplification of quide RNA cassettes with overhangs for assembly 475 1. Set up PCR reaction in 50 µl reaction volume: 476 5 – 20 ng plasmid DNA 477 -0.25 µM primer (each) 478 -250 µM dNTPs (each) 479 -480 0.5 µl Herculase II -Fill up to 50 µl with nuclease free water. 481 482 2. Carry out the PCR reaction with following conditions: 98 °C, 2 min; [98 °C, 30 sec; 483 55°C, 30 sec; 72 °C, 30 sec] x30 cycles; 72 °C 2 min. 3. Load the PCR products on a 1% agarose gel and purify the 412 bp fragment using a 484

485		DNA gel extraction kit.
486		
487	Digest	tion of sgRNA expression vector
488	1.	Set up digestion reaction as following:
489		- X μl plasmid DNA, pU6-(<i>Bbsl</i>)sgRNA_CAG-venus-bpA (5 μg)
490		 2.5 µl Ascl restriction enzyme
491		- 10 μl CutSmart buffer
492		- Fill up to 100 μl with nuclease-free water
493	2.	Incubate at 37°C for 1 h.
494	3.	Inactivate the restriction enzyme for 20 min at 65 °C.
495	4.	Load the digested vector on a 0.9% agarose gel and extract the linearized vector
496		backbone using a DNA gel extraction kit. Expected fragment sizes are: 5586 bp for
497		the vector backbone and 383 bp for the empty sgRNA cassette.
498		
499	Gibso	n assembly reaction
500	1.	Set up assembly reaction as following:
501		 200 ng Ascl linearized plasmid DNA, pU6-(<i>Bbsl</i>)sgRNA_CAG-venus-bpA
502		- 30 ng PCR product (each)
503		- 10 μl Gibson assembly master mix (2x)
504		 Fill up to 20 µl with nuclease-free water
505	2.	Incubate at 50 °C for 1 h.
506	3.	Perform transformation as described in section 3.1.1
507	4.	Conduct test digests with <i>NdeI</i> on five to ten plasmid mini preparations. The expected
508		fragment sizes are: for assembly of two sgRNA expression cassettes 5515 bp; 436
509		bp and 391 bp and for three sgRNA expression cassettes 5515 bp; 436 bp,391 bp
510		and 390 bp. Subject two plasmids with the correct digestion pattern for Sanger
511		sequencing using following primers:
512		pU6-(BbsI)sgRNAseqF: TTGTGTGGAATTGTGAGCGG
513		pU6-(BbsI)sgRNAseqR: GGCTATGAACTAATGACCCCG
514		
515	Option	al: To improve the transformation efficacy perform a clean-up of the assembled
516	reactio	on using a PCR purification kit, prior to transformation.
517		
518		
519	3.2 Fe	eder-free hiPSC culture conditions

Cultivation of high-quality human iPS cells requires optimal and aseptic conditions. 520 The cultures should be free of viral, mycoplasmic and bacterial contaminations and have a 521 522 normal karyotype. It is recommended to cultivate human iPSCs in antibiotic-free media to 523 avoid the overlooking of mycoplasma infections. Therefore, it is worth to emphasize the 524 importance of aseptic culture conditions. The optimal growth conditions for human iPS cells are in a humidified, hypoxic incubator equipped with a HEPA-filter at 37°C with 1-5 % O₂ and 525 5 % CO₂. Feeder-free iPS cell culturing requires special culture media and culture plate 526 coatings. Since different hiPSC lines may demand different conditions, it is recommended to 527 test multiple commercially available hiPSC media and coatings. Pluripotent stem cells, such 528 529 as hiPSCs have a doubling time of 18-20 h and should therefore be passaged every 3 to 4 530 days. If the culture becomes over-confluent, iPS cells tend to grow as multi-layers and spontaneously differentiate. Induced pluripotent stem cells are sensitive to environmental 531 changes, thus monitor the culture on a daily base. To keep the culture in high-quality 532 condition, it is recommended to reduce the time of cells being outside the incubator to a 533 minimum. When exposed to stress by e.g. dissociating to single cells or transfection, iPS 534 cells induce apoptosis by activation of the ROCK (Rho-associated protein kinase) pathway. 535 To avoid cell death a ROCK inhibitor (Y-27632) should be added to the culture medium 536 overnight, when the cells are transfected or passaged. The addition of ROCK inhibitor 537 changes the morphology of the iPSCs, cells will grow extensions and look fibroblast-like. 538 These changes are reversible and will vanish when Y-27532 is removed. 539

540

541 The following protocol is optimized for the healthy donor-derived hiPS cell lines: MIRJT7i-542 mND2-0 (WiCell), Kolf-2 (HipSci), XM001 (Helmholtz Center Munich) and BCRT#1 (Berlin-543 Brandenburg Center for Regenerative Therapies).

- 544
- 545 3.2.1 General feeder-free human iPSC culture
- 546 1. Culture hiPSCs on cell culture plates pre-coated with an appropriate coating (e.g.
- 547 Matrigel Matrix, Fisher Scientific or truncated rhVitronectin (VTN-N), Life 548 Technologies).
- 549 2. Culture in appropriate medium (e.g. Essential 8 Medium).
- 550 3. Change medium on a daily basis, when using Essential 8.
- 4. Passage the cells when they reach 60 % to 80 % confluency.
- 552 5. hiPS cells can be passaged either using dissociation buffer as patches for 553 maintenance or using Accutase as single cells, when transfection or FACS 554 enrichment is desired.

555

556 Nevertheless, even properly handled hiPSC cultures might start to expose differentiated 557 cells. Such cells appear as fibroblast-like outgrowths at the edge of hiPSC colonies. 558 Contamination by differentiated cells can be eliminated by selectively transferring the hiPSC 559 culture to a new pre-coated cell culture plate using ReLeSR according to the manufacturer's 560 manual.

561

562	3.2.2 F	Passaging hiPSC using dissociation buffer
563	1.	Remove medium and wash the cells once with DPBS.
564	2.	Add 0.5 ml dissociation buffer (see 2.3.13) per well of a 6-well plate and incubate for
565		3-5 min at 37 °C.
566	3.	When colonies begin to detach at the edges, remove the dissociation buffer and add
567		0.5 ml of Essential 8 medium.
568	4.	Detach cells by tapping the plate and gently flush them off with medium using a
569		pipette.
570	5.	Pipet carefully 2-3 times to break bigger cell clumps into small ones.
571	6.	Resuspend the cells in appropriate volume of medium (optional: including 10 μM
572		ROCK inhibitor) and plate the cells on cell culture plate with an appropriate coating.
573	7.	Change medium the following day.
574		
575	3.2.3 F	Passaging hiPSC using Accutase
576	1.	Remove medium and wash the cells once with DPBS.
577	2.	Add 0.5 ml Accutase per well of a 6-well plate and incubate for 3-5 min at 37 $^\circ$ C.
578	3.	When colonies begin to detach and fall apart, add 2 ml Essential 8 Medium
579		supplemented with 10 µM with ROCK inhibitor.
580	4.	Pipet carefully up and down to break cell patches to single cells and spin down at 300
581		g for 4 min.
582	5.	Resuspend in appropriate volume of medium including 10 μ M Y-27632 and plate the
583		cells on cell culture plates with appropriate coating.
584	6.	Change medium the following day.
585		
586	3.2.4 (Cryopreservation of hiPSC
587	1.	Detach hiPS cells using dissociation buffer as previously described.
588	2.	Very carefully resuspend the colonies in 0.75 ml of Essential 8 medium per well,
589		leaving the colonies as large as possible.

590	3.	Add 0.75 ml cold Essential 8 medium supplemented with 20 % DMSO drop by drop to	
591		the freezing vial and swirl gently (final DMSO concentration: 10%).	
592	4.	Distribute the cell suspension to three cryopreservation tubes, each with 500 μ l.	
593	5.	Put cryovials into a freezing container (e.g. Mr. Frosty, Nalgene) and freeze at -80 $^\circ C$	
594		for 24 h before shifting the vials to liquid nitrogen for long term storage.	
595	<u>Optior</u>	al: Alternatively to growth medium supplemented with 10% DMSO, BamBanker can be	
596	<u>used a</u>	as cryopreservation medium. The usage of BamBanker increases the viability.	
597			
598	3.2.5	Гhawing hiPSC	
599	1.	Remove the cryovial containing the frozen cells from liquid nitrogen and transport	
600		them to the cell culture lab on dry ice.	
601	2.	Immediately place it into a 37°C water bath.	
602	3.	Thaw cells by gently swirling the vial in the water bath until there is only a small piece	
603		of ice left.	
604	4.	Wipe the outside of the tube with 70 $\%$ ethanol quickly and transfer the vial to the	
605		laminar flow hood.	
606	5.	Add 1 ml pre-warmed Essential 8 medium in a dropwise manner to the cells and	
607		incubate for 1 min.	
608	6.	Transfer the thawed cells to a 15 ml centrifugation tube and add another 4 ml	
609		Essential 8 medium.	
610	7.	Centrifuge the cell suspension at 200 g for 4 min.	
611	8.	Aspirate the supernatant without disturbing the cell pellet.	
612	9.	Gently resuspend the cells in Essential 8 medium.	
613	10	. Plate the cells on cell culture 6-well plates pre-coated with an appropriate coating in	
614		Essential 8 medium supplemented with 10 μ M Y-27632. Depending on the density	
615		the cells were frozen at, we recommend to plate the cells at different dilutions, 1:2	
616		and 1:10.	
617	11	. Change the medium the following day to Essential 8 medium without Y-27632.	
618			
619	3.3 Tr	ansfection of CRISPR/Cas9 constructs into hiPS cells	
620		We suggest using unmodified hiPSC lines for editing of a single target gene (Workflow	
621	A) or ι	using hiPS cell lines expressing Cas9 under a strong doxycycline inducible promoter if	
622	one ir	ntends to modify multiple genes simultaneously (Workflow B). In our laboratory we	
623	genera	ated several different hiPS cell lines carrying an inducible Cas9 in the safe harbor locus	
624	AAVS1, based on Gonzales et al. [19] (cell lines available upon request). Instead of using the		

M2rtTA transactivator we used the TRE-3G Tet-on transactivator that drives a stronger expression upon doxycycline induction (Fig. 2C). The inducible Cas9 system is a versatile tool to generate complex genotypes in a one-step experiment (Fig. 2B). Since the cells are already equipped with Cas9, smaller plasmids carrying only the sgRNAs and a reporter/selector have to be transfected transiently, which improves the transfection efficiency (Fig. 5).

631 An efficient transfection of a CRISPR nuclease and the sgRNA is indispensable for successful genome editing. The choice of a certain transfection method depends upon its 632 efficacy in a hiPS cell line of interest as well as on the viability of the cell line, when exposed 633 634 to the transfection method. Generally small vectors < 8 kb can be more efficiently transfected 635 and induce less cell death than large vectors >8 kb (Fig. 5A and B). However, where some lines can be efficiently transfected by reagent or chemical-based transfection methods such 636 as Lipofectamine 3000, others respond well to electroporation. Thus, transfection conditions 637 have to be optimized for different iPS cell lines as shown in Figure 5. 638

639

640

641

- Figure 5 -

Here we describe three different transfection methods generally used for CRISPR/Cas9-based gene editing. These methods are based on transient transfection of plasmids expressing Cas9 and/ or sgRNAs. Depending upon the nature of the planned experiment, multiple sgRNAs can be transfected simultaneously to achieve multiplex gene editing. To facilitate generation of gene edited clones we recommend to use either a fluorescent marker if FACS sorting is feasible or selection markers like puromycin or hygromycin on the plasmid encoding for Cas9 and sgRNA to enrich transfected cells.

This protocol is based on hiPS cells grown in feeder-free conditions in Essential 8 culture media in a 6-well cell culture plate.

651 652

653 **3.3.1 Reagent-based transient transfection using Lipofectamine 3000**

- 654
- Prepare plasmid DNA at a concentration of 0.5-1 μg/μl in deionized water or TE
 buffer. The DNA used for transfection should be of high quality as poor quality of DNA
 might decrease the efficacy of transfection.
- 658 2. One day prior to transfection dissociate the cells using Accutase and seed $5x10^4 1x10^5$ cells per well of a pre-coated 6-well plate as single cells or in small clumps.

660		Cultivate the cells in fresh medium containing 10 μ M Y-27632 overnight.
661	3.	Change the medium ahead of transfection.
662	4.	Dilute depending on the size of the plasmid between 1 μg and 2.5 μg DNA in 125 μl
663		of Opti-MEM reduced serum medium in tube labeled as A. Add 3.75 μI of p3000
664		reagent and mix well. Dilute 5 μI Lipofectamine 3000 reagent in 125 μI of Opti-MEM
665		reduced serum medium in tube B. Diluted Lipofectamine 3000 should be used within
666		15 minutes. Longer times can result in decreased transfection efficacy.
667	5.	Add the content of tube A to tube B, mix well by pipetting and incubate at room
668		temperature for 5 minutes.
669	6.	Add the DNA-lipid complex to one well of a 6-well plate in a dropwise manner and
670		gently rock the plate to ensure its distribution over the whole well. Some cell lines are
671		sensitive to Lipofectamine 3000.
672		Optional: The addition of 5 μ M Y-27632 to the culture medium for 24 h increases
673		viability.
674	7.	Change medium on the following day. When iPS cells harboring a doxycycline
675		inducible Cas9 were used, feed the cells for 48 h with medium supplemented with 1
676		μg/ml doxycycline.
677	8.	Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis
678		of bulk population (see section 3.5 for the method of choice for analysis).
679	9.	
680		
681	3.3.2 E	Electroporation-based transient transfection using the Neon system
682	The fo	llowing protocol describes the electroporation procedure using the 100 μ l Neon
683	Transf	ection kit, aiming for a 6-well plate format. The DNA used should be of high quality to
684	achiev	e the optimal results.
685		
686	1.	Prepare highly concentrated plasmid DNA (1-5 $\mu\text{g}/\mu\text{I})$ in deionized water or TE buffer.
687		The amount of plasmid DNA should not exceed 10% of the total volume of
688		resuspension buffer.
689	2.	Coat a 6-well plate with appropriate coating.
690	3.	Pre-warm Essential 8 medium containing 10 μM Y-27632.
691	4.	Change the medium ahead of transfection.
692	5.	Dissociate the cells using Accutase and spin down for 4 min at 300 g.
693	6.	Wash the cell pellet once with PBS.
694	7.	Dilute 5.5 µg total plasmid DNA in 110 µl buffer R (part of Neon transfection kit) in a

- 695 microcentrifuge tube.
- 8. Resuspend 6x10⁵ cells in 110 µl buffer R containing the DNA. Care should be taken
 while resuspending for no air bubbles will be formed. Presence of air bubbles will lead
 to unsuccessful electroporation.
- 699 9. Fill 3 ml of electrolytic buffer E2 (provided with the Neon kit) into a Neon tube and
 700 insert it into the pipetting station. A single Neon tube can be used up to 10 times.
- 10. Insert a 100 µl Neon tip into the Neon pipette. Make sure that the tip is adjusted
 correctly before pipetting the cell/ DNA mix.
- 11. Load the appropriate Neon program (it is advised to optimize settings for each cell
 line using a fluorescent plasmid). The electroporation parameters we generally use
 are 1 pulse at 1300 V and a duration of 30 ms.
- 706 12. Press start and wait until the procedure is complete. A single Neon tip can be used
 707 twice with the same plasmid/cell line.
- Transfer the electroporated cells to a microcentrifuge tube containing 500 μL medium
 supplemented with 10 μM Y-27632 and pellet at 300 g for 4 min.
- 14. Resuspend the cells in 600 μL fresh medium supplemented with Y-27632. Plate 100
 μL cell suspension into one well of a pre-coated 6-well plate containing 2 ml medium
 supplemented with 10 μM Y-27632.
- 713 15. Rock the plate gently and incubate the cells.
- T14 16. Change medium the following day. When iPS cells harboring a doxycycline inducible
 T15 Cas9 were used, feed the cells for 48 h with medium supplement with 1 μg/mL
- 716 doxycycline.
- 717 Optional: The addition of 5 µM Y-27632 to the culture medium for 24h on the day
 718 after transfection improves viability.
- 719 17. Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis720 of bulk population (section 3.5).
- 721

722 **3.3.3 Electroporation-based transient transfection using the Gene Pulser system**

- 1. Prepare highly concentrated plasmid DNA (1-5 μ g/ μ l) in deionized water or TE buffer.
- 2. Change the medium ahead of transfection.
- 3. Coat a 6-well plate with appropriate coating.
- 4. Pre-warm Essential 8 medium containing 10 μM Y-27632.
- 5. Pre-chill a 0.4 cm electroporation cuvette.
- Dilute the appropriate amount of plasmid DNA (20-40 μg per plasmid, if multiple
 plasmids are transfected we recommend to use up to 100 μg DNA) in 850 μl DPBS

730 and chill on ice. 7. Dissociate the cells using Accutase and spin down for 4 min at 300 g. 731 8. Wash the cells once with DPBS, take an aliquot for counting and pellet again at 300 g 732 733 for 4 min. 9. Resuspend at16x10⁶ cells/ ml in ice-cold DNA/ PBS dilution and carefully transfer 800 734 µl of it to the electroporation cuvette containing the DNA, avoid air bubble formation. 735 736 10. Incubate on ice for 5 minutes and proceed with electroporation. We generally use following parameters: single pulse at 300 V and 500 μ F, the time constant should be 737 between 10 ms and 15 ms. It is advised to optimize settings for each cell line using a 738 739 fluorescent plasmid. 740 11. Immediately after the pulse add 500 µl of pre-warmed culture medium supplemented with ROCK inhibitor Y-27632 to the cells. 741 12. Transfer the cells to a microcentrifuge tube and pellet them by centrifugation. 742 13. Resuspend the cells in 600 µl fresh medium containing Y-27632 and plate 100 µl cell 743 suspension into one well of a pre-coated 6-well plate containing 2 ml medium 744 supplemented with 10 µM Y-27632. 745 14. Rock the plate gently and incubate the cells. 746 15. Change medium the following day. When hiPS cells harboring a doxycycline inducible 747 Cas9 were used, feed the cells for 48 h with medium supplement with 1 µg/ml 748 749 doxycycline. Optional: The addition of 5 µM Y-27632 to the culture medium for 24 h improves 750 751 viability. 752 16. Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis 753 of bulk population (see section 3.5). 754 755 3.4 FACS enrichment and clonal isolation hiPS cells Selecting cells that were successfully transfected improves the rate of gene editing cells. In 756 757 758

Selecting cells that were successfully transfected improves the rate of gene editing cells. In this protocol, we describe the enrichment of transfected cells by FACS (Fig. 6). If there is no opportunity to utilize FACS, other selection methods e.g. using antibiotics like puromycin or hygromycin can be applied. Cultivating hiPS cells in 50 % conditioned medium dramatically increases cell survival of the FACS process [47]. We have observed that the usage of conditioned medium increases the viability of single seeded iPS cells in low density and prevents the cells from spontaneous differentiation. Nevertheless, the procedure of FACS enrichment might induce cell stress therefore we suggest processing the cells as fast as possible. To avoid contaminations during FACS we suggest using penicillin and streptomycin

765	as well as gentamicin. The dissociated cells should not be kept on ice for longer than 45			
766	minutes.			
767				
768		- Figure 6 -		
769				
770	3.4.1 F	FACS enrichment of transfected hiPSC		
771	1.	Prepare post-FACS medium: 50 % fresh Essential 8 medium, 50 % conditioned		
772		Essential 8 medium (medium that was conditioned for 24 h on hiPS cells with 50-80		
773		% confluency of the same line and filtered through a 0.45 μm PTFE membrane filter)		
774		supplemented with 10 μ M Rock inhibitor Y-27632 , RevitaCell Supplement (1X),		
775		Pen/Strep (1X), and Gentamicin (1X).		
776	2.	Coat a 6-well plate with appropriate coating.		
777	3.	For each FACS sample, prepare 1.5 ml microcentrifuge tube with 1 ml post-FACS		
778		medium and keep on ice.		
779	4.	Pre-warm Essential 8 medium containing 10 μ M Y-27632, Pen/Strep (1X), and		
780		Gentamicin (1X).		
781	5.	Dissociate cells using Accutase and spin down for 4 min at 300 g.		
782	6.	Resuspend the cells thoroughly by pipetting the cells 5-10 times to achieve a single		
783		cell suspension. We suggest resuspension in 200 to 300 μ l medium per well of a 6-		
784		well plate at 70 % - 80 % confluency		
785	7.	Strain through a strainer cap with a mesh size of 35 μm into a FACS tube.		
786	8.	Put cells on ice and proceed with FACS immediately.		
787	9.	Depending on the nature of your experiment and the chosen fluorophore, sort for your		
788		desired cell population directly into a cooled 1.5 ml microcentrifuge tube containing 1		
789		ml of post-FACS medium.		
790	10	. Seed 300-500 cells per well in 2 ml post-FACS medium in a 6-well format as quickly		
791		as possible after sorting. Prepare several wells for each sample.		
792	11	. Make sure single cells are evenly distributed throughout the well to ensure		
793		emergence of single cell derived colonies.		
794	12	Additionally, seed the remaining cells at a higher density on a separate well. This well		
795		can be used after expansion for gDNA extraction from the sorted bulk population and		
796		subsequent PCR based genotyping to determine the rough gene targeting efficacy for		
797		example by RFLP. This can be very helpful to determine the number of single clones		
798		that need to be analyzed for the specific gene targeting event.		
799	In case	e of low gene targeting efficacy, two rounds of transfection and sorting can be of		

800	advantage to enrich for gene edited single clones. Therefore, seed all positive cells
801	coming out of the first sort. Once the cells have recovered, and have reached an
802	appropriate confluency, transfect them again, followed by a second sorting step.
803	
804	3.4.2 Clonal isolation of hiPSCs
805	1. Culture the sorted cells for 5 days in 50 % conditioned and 50 % fresh medium until
806	small colonies emerge. Change medium daily.
807	Optional: The addition of 5 µM Rock inhibitor Y-27632 for 1 to 2 days to the medium
808	(50 % conditioned and 50 % fresh medium) improves viability of single cell derived
809	clones.
810	 At day 6 switch to regular Essential 8 medium and continue with daily feeding.
811	3. Closely monitor the growth of the single cell derived colonies to exclude the possibility
812	that neighboring colonies fuse together. This can be done by circling neighboring
813	colonies on the bottom side of the well with a marker pen.
814	4. After approximately 7 to 10 days colonies are large enough for manual picking.
815	5. Gently scratch the colonies into smaller, checkered patches either using a small
816	needle or using a 10 μl pipette tip utilizing a stereo microscope in a sterile
817	environment.
818	6. Transfer the patches of one clone to one well of a pre-coated 12-well plate containing
819	pre-warmed medium supplemented with 10 μ M Y-27632.
820	7. Gently resuspend the cell patches by pipetting up and down with a 1000 μ l tip. After a
821	few days colonies may need to be dissociated with EDTA within the plate to break
822	apart the large colony and avoid differentiation of the cells.
823	8. As soon as the cells build larger colonies, split each clone on 2 separate wells in
824	either 12- or 6-well format in a 20 % to 80 % ratio. Use one plate (80 %) for further
825	expansion and subsequent gDNA extraction, followed by PCR based genotyping to
826	detect CRISPR/Cas9 edited clones.
827	9. Meanwhile, you can freeze the second plate as a back-up (20 %). It is recommended
828	to use the BamBanker cryopreservation solution instead of 10 % DMSO when
829	freezing iPSCs in a multiwell plate instead of cryovials.
830	10. Aspirate the medium and cover the wells with dissociation buffer. Incubate the plate
831	for 3-5 min at 37 $^\circ$ C. Aspirate the Dissociation reagent and add 0.3-0.5 ml of
832	BamBanker cryopreservation solution. Gently dissociate the colonies by repeated
833	pipetting. Seal the plate with Parafilm and store the plate at -80 $^\circ C$ in a Styrofoam box
834	until further use.

11. In most cases, cryo-preservation of the single cell derived clones after further

expansion is recommended as a back-up (section 3.2.4).

836 837

838 3.5 Analysis techniques of CRISPR/Cas9 induced modifications

839 There is a variety of methods to analyze genome modifications. Table 1 summarizes the most common methods for analyzing indels or point mutations. Most of them are based on 840 841 PCR amplification of the targeted region, and in such cases optimization of the PCR reactions is a prerequisite for clear analysis results. For successful PCR we recommend 842 using a high fidelity polymerase such as Herculase II (Agilent) or Q5 (NEB). We suggest to 843 use fragment analysis or Sanger sequencing followed by TIDE [48] analysis for indel 844 845 detection in clonal derived cells. To detect indels in bulk populations we use deep sequencing of fragments. For evaluation of inserted point mutations we recommend RFLP to 846 pre-screen bulk populations or single cell derived clones and Sanger or deep sequencing for 847 verifying the correct integration of the targeting donor. 848

849

850 851

- Table 1 -

852 **3.5.1 PCR design**

Depending on the analysis assay the requirements on the PCR reaction differ mainly in the 853 size of the PCR product. The major requirement for all analysis methods is a specific 854 855 amplification of the desired genomic locus. Therefore while designing the primers heterozygous mutations or SNPs as well as repetitive sequences should be avoided. When 856 857 using Sanger sequencing followed by TIDE analysis the smallest recommended product 858 length is 250 bp. To guarantee adequate sequence decomposition, the sgRNA targeting site should be 150 bp – 400 bp distant from the sequencing primer binding site. For fragment 859 analysis, amplicon sizes ranging from 200-650 bp can be used to ensure a precise resolution 860 up to a single base. However, the smaller the amplicons are the higher the resolution will be. 861 For the RFLP assay the PCR should be designed in a way that product length should be in a 862 range of 400-1200 bp and the sgRNA target site is off-set of the amplicon center. 863

864

865 **3.5.2 PCR reaction and purification**

Genomic DNA (gDNA) can be extracted from hiPS cells of either a semi-confluent well of a
6-well plate or a confluent well of a 12-well plate with the Wizard (Promega) or other DNA
purification kits. PCR reactions are carried out using 100 ng gDNA in 50 µl with Herculase II
according to manufacturer's instructions. For Sanger sequencing or fragment analysis the

PCR products are gel purified using e.g. the Wizard SV Gel and PCR Clean-Up System(Promega).

872

873 3.5.3 Sanger sequencing

Purified PCR products are prepared for sequencing using 20 pMol of sequencing primer and
60 -150 ng amplicon. The sequencing can be conducted by a commercial provider, e.g. LGC
Genomics.

877

878 3.5.4 TIDE analysis

879 Tracking of Indels by DEcomposition (TIDE) is a method for quantitative assessment of 880 genome editing events (https://tide.nki.nl/) [48]. By aligning the sgRNA sequence to the control sequence TIDE first identifies the expected Cas9 induced double-strand break site. 881 Based on the peak heights TIDE then analyzes the abundance of aberrant nucleotides over 882 the length of the sequence. The sequences are then evaluated with a decomposition 883 algorithm to identify the insertion and deletion mutations in the subjected sequencing file. 884 Clear sequencing traces are an essential requirement for solid indel detection and 885 quantification. For the TIDE analysis the sequencing files of mutated and control samples 886 can be uploaded to the TIDE web tool as .ab1 or .scf files and analyzed with the preset 887 parameters, except for the indel size range which is reset to 20. 888

889

890 3.5.5 Fragment analysis

Fragment analysis is a useful tool to evaluate indel formation in single cell derived clones as 891 892 well as in cell populations. When loading fluorescent labeled PCR products of the edited 893 sgRNA target site on a capillary sequencer, amplicons differing in size due to small insertions or deletions can be separated with accuracy in resolution, depending on the size of the PCR 894 895 product. PCR products with a length of up to 650 bp can be separated with a resolution of a single base. For this approach, fluorescently labeled forward primers (HEX, TET or 6-FAM) 896 897 must be used to amplify the region of interest. Subsequently the PCR products are loaded on an agarose gel, purified using a PCR Clean-Up System (Promega) and 60 - 150 ng of the 898 899 purified samples are subjected to analysis (SMB Service GmbH, Berlin, Germany) using LIZ-900 500 size standard.

901

902 3.5.6 RFLP assay

RFLP assays can be applied to assess indel formation when a restriction enzyme recognition
site is located at the sgRNA targeting sequence, adjacent to the site of DSB, or to screen for

HDR events when additional restriction sites are inserted in the donor template. The 905 amplicon size for this assay type should range from 400 bp to 1200 bp whereas the 906 restriction site should be off-set to the center to facilitate the detection of both restriction 907 908 fragments. The PCR products can be digested without further purification steps when 909 choosing restriction enzymes that are active in the PCR buffer. For the digestion 20 µI PCR 910 product are combined with 5 units of the selected enzyme, incubated at 37 °C for 1 h and 911 analyzed on a 1.5 % agarose gel. RFLP analysis can also be combined with fragment analysis, when using fluorescent labeled primers for amplification. We recommend RFLP 912 assays to determine the abundance of mutagenesis events in a bulk population, to estimate 913 914 the efficacy of a CRISPR/Cas9 experiment and decide how many clones to analyze.

915

916 **3.5.7 T7E1 Assay**

The T7E1 and Surveyor assays can be used to assess indels and heterozygous point 917 mutations in single cell derived clones as well as in bulk populations. Furthermore these 918 assays are useful tools to test the efficacy of sgRNAs in cell lines like 293 cells. Both assays 919 920 are used to detect DNA hetero-duplex formations of PCR amplicons by hybridization of mutant and wild type sequences or two different mutant sequences. These mutation-921 sensitive methods fail to detect homo-duplexes e.g. formed by two identical mutant 922 sequences. Similar to RFLP the amplicon size for T7E1 assay should range from 400 bp to 923 1200 bp with the CRISPR/Cas9 targeting site off-set to the center of the amplicon. After the 924 925 PCR reaction a clean-up step was performed and subsequently the purified fragments were denatured for 5 min at 98 °C in a heat block and re-annealed by switching of the heat block 926 927 for 1-2 h. 200 ng PCR product was digested with 5 units T7E1 (NEB) for 15 min at 37 °C. After incubation the samples were immediately transferred to ice and supplemented with gel-928 loading-buffer. The digested fragments were separated on a 1.5 % agarose gel. In our 929 930 experience the T7E1 assay often results in nonspecific cleavage products when applied to iPS cell derived gDNA, hence often needs further optimization steps for different loci. 931 Therefore we recommend using RFLP (section 3.5.6), Fragment analysis (section 3.5.5) or 932 933 TIDE analysis (section 3.5.4).

- 934
- 935

936 **3.5.8 Off-target analysis**

937 Off-target sites of sgRNA are predicted using CRISPOR or CRISPR DESIGNER 938 (http://crispr.mit.edu/). In general off-target sites with an off-target hit-score > 0.9 are 939 analyzed by PCR amplification and Sanger sequencing followed by TIDE analysis. In our experiments we have observed no off-target effects when designing sgRNAs with the web tool CRISPOR (http://crispor.tefor.net/) and choosing sgRNAs with specificity scores > 60 and efficacy scores (Fusi score) > 45. Although CRISPR/Cas9 induced off-target effects are rare in hiPSCs, especially since safer and more accurate sgRNA designing web tools are available, we encourage the analysis of such potential effects in genome edited cells. In particular undesired mutations may distort the results when the edited cells are subjected to a phenotypic comparison with control cells.

947 948

949 **<u>4. Results</u>**

950 Since expansion and analyzing of genome edited iPSC clones is laborious it is important to pick and analyze a feasible number of clones. In the following section we 951 summarize the experience we gathered in our lab to provide guidance in regard to the 952 number of clones to be analysed. The following data are based on three independent 953 sgRNAs each targeting an individual native locus. The results we present in section 4.1 are a 954 summary of experiments where a single guide of each three was used at a time (Workflow 955 A). In section 4.2 we summarize experiments that implement all three guides at once 956 957 (Workflow B). At this point we would like to note that targeting efficacies are, among others, dependent on the locus of interest, cell lines and the performance of the selected sgRNA. 958 Therefore, we consider our presented data as a reference point and not as a universal rule. 959

960

961 4.1 Results obtained with Workflow A

In the course of optimizing gene targeting with transient transfection of Cas9 and 962 963 sgRNA (Workflow A) we started with an approach using a plasmid vector carrying Cas9 together with a fluorescent reporter and a separate vector encoding only for a single sgRNA 964 without any selection gene. The hiPSCs were enriched by FACS for the fluorescent reporter 965 48h after transfection. With this approach we could enrich only the fraction of cells 966 transfected with the nuclease but not the guide RNA (Table 2; separate vectors). We 967 analyzed 176 sorted, single cell derived clones and obtained only two mutagenized clones 968 969 (1 %) where one clone was targeted on both alleles and the second clone on one allele. In our next approach we transfected hiPSCs with combined vectors, coding for Cas9, the 970 971 sgRNA cassette as well as a fluorescent reporter (pU6-(Bbs/)sgRNA CAG-Cas9-venus-bpA or pU6-(Bbs/)sqRNA CAG-Cas9 EF1-TagRFP). Using this strategy, we could enrich for 972 cells carrying Cas9 and the guide RNA. By this method we achieved a mutagenesis rate of 973 17 % in 116 analyzed clones. 70 % of the mutagenized clones were targeted on both alleles 974

and 30% only on one (Table 2; combined vector).

Based on these results, we conclude that when it is intended to introduce frameshift indels in one single gene using transient transfection of Cas9 and sgRNA carrying fluorescent reporter vectors (Workflow A) followed by FACS enrichment, 24 cell clones is a reasonable number to obtain 2 to 4 clones with mutations on both alleles.

- 980
- 981

<u>- Table 2-</u>

982

983 4.2 Results obtained with Workflow B

In experiments where we used the doxycycline inducible Cas9 system with transient transfection of fluorescent reporter vectors that express three different sgRNAs (Workflow B) followed by FACS enrichment, we observed indel mutations in all three loci (Parkin, Dj1, Pink1) in two out of 24 single cell derived hiPS cell clones (8 %). In one clone we detected indels in two loci (4 %). None of the analyzed clones were mutated in only one locus. 71 % of targeted loci were mutated in a bi-allelic manner (Table 3; Single round).

Additionally, we conducted an experiment where we followed Workflow B as described above, but co-transfected the plasmid pCAG-Trex2-bpA to co-express the end-processing enzyme Trex2. This experiment resulted in a targeting efficacy of 15 % for triple and 15 % for double gene mutagenesis (20 clones analyzed in total). None of the analyzed clones were mutated in a single locus only. Analogous to the previous experiments the majority of the mutated loci were targeted on both alleles (Table 3; Single round +Trex2).

Finally we could improve the targeting efficacy by repeating the transfection and FACS sorting procedure a second time (Table 3; Second round). In 15 of in total 57 single cell derived human iPS cell clones we could detect triple gene mutagenesis (26 %). 7 clones were targeted on two loci (12 %) and 4 clones carried indels in only one of the targeted loci (7 %). In accordance with our previous observation the majority of mutations occurred on both alleles of a locus.

-Table 3-

1002

1003

Thus we recommend based on our experience, when it is intended to introduce frameshift indels in multiple loci, we suggest using the doxycycline inducible Cas9 system with transient transfection of sgRNA carrying fluorescent reporter vectors (Workflow B) followed by FACS enrichment. In this case we recommend selecting 36 to 48 clones to have a feasible number of multiple edited cell clones. To minimize the number of clones to analyze during multiplex gene editing we suggest: a) co-transfection with the plasmid pCAG-Trex2-

bpA for expression <u>of</u> the end-processing enzyme Trex2 and b) repeating the transfection and FACS enriching procedure a second time (sections 3.3 and 3.4). In this regard analyzing 16 to 24 clones should be adequate to obtain various clones with mutations on both alleles for the desired loci (Table 2 and Table 3). If precise genome editing is desired (HDR events) we suggest to first determine the efficacy of mutagenesis events in a bulk population e.g. by RFLP analysis and depending on that estimate the number of clones to be picked and analyzed.

1017

1018 **4.3 Quality of targeted human iPSCs**

1019 To monitor, if the CRISPR/Cas9 based gene targeting strategies we describe here have an 1020 influence on the genetic stability of the targeted cells, we performed SNP analysis based virtual karyotyping on edited human iPS cells. The karyotyping was performed with the 1021 1022 Infinium OmniExpressExome-8 v1.2 BeadChip system that covers over 960,000 common SNPs over the human genome. We analyzed two hiPSC clones that were successively 1023 1024 targeted at the AAVS1 locus to initially create doxycycline inducible Cas9 expressing hiPSCs and afterwards at three native loci by two rounds of transfection followed by FACS 1025 1026 enrichment. Both characterized clones were successfully targeted on both alleles of all three 1027 loci.

1028 The SNP based karyotyping revealed no chromosomal aberrations. We detected eight SNPs 1029 that were absent in an early passage of the parental cell line (data not shown). It is unclear if 1030 these SNPs emerged during cultivation or are an artifact of the editing process. However, 1031 pluripotent stem cells are generally considered as genetically unstable and we could 1032 demonstrate that our editing method does not exacerbate this phenomenon.

Additionally we analyzed the edited clones for potential mutations at predicted CRISPR/Cas9 off-target sites for the individual sgRNAs used here (section 3.5.8). We analyzed the most relevant loci with a hit-score > 0.9 regarding to CRISPOR and CRISPR DESIGNER. We could not detect any mutation at these sites.

- 1037
- 1038
- 1039

-Figure 7-

1040 We subjected targeted cell clones mentioned above to immunostainings for the 1041 pluripotency markers OCT4, NANOG, SOX2 and SSEA4 (Figure 7A). We confirmed that 1042 targeted hiPSCs express common pluripotency markers.

1043 Furthermore we examined the differentiation potential of hiPS cells, targeted with our 1044 workflow, to the ectodermal lineage. We performed a neuronal differentiation assay with 1045 gene targeted hiPSCs and could demonstrate that these cells are capable to differentiate to1046 TUJ1 and TH expressing neuronal cells (Figure 7B).

- 1047
- 1048
- 1049

1050 <u>5</u>. Conclusion

1051 Two groundbreaking discoveries of the past decade, human iPS cell technology and gene 1052 editing using CRISPR/Cas9, provide new opportunities for researchers. Combining both allows us to study the function of a gene in a human system in the context of specific 1053 1054 diseases or even gene therapeutically applications by correcting gene defects in patient 1055 cells. Using CRISPR/Cas9 in immortalized, fast-cycling cell lines is well established. However, using this system in hiPS cells is more challenging due to the sensitive 1056 1057 requirements of hiPS cells to maintain culture pluripotency. Although generating precise 1058 knockins via HDR is relatively inefficient, the possibility to use selection markers or 1059 introducing recognition sites for restriction enzymes in the repair template facilitates screening for successfully targeted cells. CRISPR/Cas9 mediated gene disruption by 1060 introducing indel mutations on the other hand occurs more frequently but screening of clonal 1061 1062 derived cells is more laborious.

1063 We describe here a simple and efficient workflow for clonal isolation and screening of 1064 genome engineered human iPS cells without prior drug selection. Applying this workflow to 1065 hiPS cell lines equipped with an inducible Cas9 under a strong promoter even enables the 1066 generation of multiple targeted mutant alleles in a single experiment.

1067

1068 Acknowledgements

We thank Dr Harald Stachelscheid (Berlin-Brandenburg Center for Regenerative Therapies)
for kindly providing us the iPSC line BCRT#1 and Dr Heiko Lickert (Helmholtz Center
Munich) for kindly providing the iPSC line XM001. We also thank Dr Sebastian Diecke who
performed karyotyping and SNP analysis (iPSC Core Facility, Max-Delbrück-Center, Berlin).
PL was supported by National Science Center, Poland Grant No. 2016/22/M/NZ2/00548..

- 1074
- 1075
- 1076
- 1077
- 1078

1079 **Tables**

1080 Table 1 Summary of analysis methods for genome editing events

Assay	Advantage	Disadvantage	Application	
Sanger/Tide	Quick and simple;	Low accuracy for	Indel detection in clonal	
	High accuracy for single	quantification in bulk	derived cells	
	cell derived clones	population		
Cloning/Sanger	High accuracy	Very laborious	For verification of	
			knockins or indels in	
			single cell derived clones	
Fragment Analysis	Quick and simple;	Requires special	Indel detection in clonal	
	High accuracy for single	equipment/service	derived cells or bulk	
	cell derived clones		populations	
RFLP	Quick and simple; High	Low accuracy for	Detection of knockins or	
	accuracy for single cell	quantification on bulk	indels in single cell	
	derived clones	populations	derived clones or bulk	
			populations	
Deep Seq	High accuracy	Requires special	Detection of KI or indels	
		equipment/service	in bulk populations and	
			single cell derived clones	
T7E1/Surveyor	Quick and simple	Need thorough	To pre-test sgRNAs in ce	
		optimization	lines	

1090 Table 2 Results of gene editing in hiPSC using Workflow A

<u>Approach:</u> Workflow A	<u>Analyzed</u> <u>clones</u>	<u>Single gene</u> mutagenesis	<u>Mono allelic</u> <u>events</u>	<u>Bi alleleic</u> <u>events</u>
Separate vectors: Cas9-fluorescent reporter and sgRNA	<u>176</u>	<u>1%</u>	<u>50%</u>	<u>50%</u>
<u>Combined vector:</u> <u>Cas9-sgRNA-</u> fluorescent reporter	<u>116</u>	<u>17%</u>	<u>30%</u>	<u>70%</u>

1092 Table 2 Results of gene editing in hiPSC using Workflow B

<u>Approach:</u> Workflow B	<u>Analyzed</u> <u>clones</u>	<u>Single gene</u> <u>mutagenesis</u>	Double gene mutagenesis	<u>Triple gene</u> <u>mutagenesis</u>	Mono allelic events	<u>Bi alleleic</u> <u>events</u>
Single round: inducible Cas9 with transient sgRNA- fluorescent reporter	<u>24</u>	<u>0%</u>	<u>4%</u>	<u>8%</u>	<u>29%</u>	<u>71%</u>
Single round +Trex2: inducible Cas9 with transient sgRNA- fluorescent reporter and mTrex2	<u>20</u>	<u>0%</u>	<u>15%</u>	<u>15%</u>	<u>33%</u>	<u>67%</u>
Second round: inducible Cas9 with transient sgRNA- fluorescent reporter and Trex2	<u>57</u>	<u>7%</u>	<u>12%</u>	<u>26%</u>	<u>16%</u>	<u>84%</u>

1099 Figure Legends

1100 Figure 1 The CRISPR/Cas9 nuclease system

A: Cas9 and sgRNA recognize 20 nt target sequences located upstream of the invariant 3 bp NGG PAM sequence (red letters). B: If a target sequence is found upstream of the PAM site, each of the RuvC and HNH nuclease domains of Cas9 cut one strand of the target DNA, creating a DSB (triangles). C: DSBs in target genes can be either repaired by NHEJ, leading to small sequence deletions and gene knockout alleles. Precise sequence modifications (Knockin alleles) are introduced by HDR with the homology regions of DNA repair templates, either an ssODN or plasmid vector.

1108 1109

Figure 2 Strategies for intracellular delivery of components required for CRISPR/Cas9 mediated gene editing

A Transfection of an expression vector carrying both a sgRNA cassette and the Cas9 gene 1112 enables gene editing via DSBs in wildtype cells. **B** For transgenic cell lines that express 1113 Cas9 under a doxycycline-inducible promoter, transfection of a vector encoding for sgRNA(s) 1114 only is sufficient. Successive administration of doxycycline activates Cas9 expression. This 1115 approach achieves improved efficacy at targeting more than one locus. A reporter gene 1116 included in either of these strategies allows for the identification of transfected cells. C 1117 1118 Doxycycline (DOX) dependent expression of Cas9 is provided by a modified AAVS1 locus. 1119 While the DOX-inducible promoter TREtight and the Cas9 gene are knocked in between the first two exons of the PPP1R12C gene (AAVS1 locus) on one allele, the other allele harbors 1120 1121 the Transactivator gene rtTA3 expressed under the constitutively active CAGGS promoter. Presence of DOX mediates binding of rtTA to TREtight, thus activation of Cas9 expression. 1122

1123

1124 Figure 3 HDR efficacy using ssODNs of various architectures

1125 Cells of the hiPSC line BCRT#1 that heterozygously express EGFP driven by a CAG promoter from the AAVS1 locus were co-transfected with an expression vector for both Cas9 1126 1127 and sqRNA targeting EGFP and various ssODN donor templates. 1128 A Donor templates were designed to convert EGFP to BFP in case of HDR events, in symmetric (sym) [44] or asymmetric (asm) [42] fashion, with and without phosphorothioate 1129 modification (PTO) [43]. B, C Positively transfected cells were isolated by FACS, based on 1130

an RFP fluorophore included in the expression vector. 7 days post transfection HDR/ indel 1131 frequency was assessed by FACS analysis. Absent fluorescent signal corresponds to indels 1132 due to disrupted EGFP, BFP⁺ cells to successful HDR and EGFP⁺ cells indicate cells not 1133 undergoing any event. Occurrence of no event was generally low (<4%). HDR frequency of 1134 1135 both PTO-modified symmetric (6.1%) and asymmetric (4.0) ssODNs were below the efficacy of unmodified asymmetric donor templates (12.8%). The highest HDR efficacy was obtained 1136 1137 using unmodified symmetric ssODNs (20.8%). Experiments were conducted in three independent replicates; error bars represent standard error of the mean; significance as per 1138 Student's t-test: *<0.05, **<0.005, ***<0.0005. 1139

1140

1141 Figure 4 Overview on the workflow for CRISPR/Cas9-mediated generation of a

1142 transgenic hiPS cell line without drug selection

1143 Initially, vectors expressing components necessary for CRISPR/Cas9-mediated gene editing, 1144 i.e. locus specific sgRNA, a fluorescent reporter and optionally Cas9, are required. Available combined plasmids provide convenient cloning strategies to include custom sgRNA 1145 sequences. After transfection of wildtype hiPS cells with these vectors, the included 1146 fluorescent reporter enables enrichment of successfully transfected cells utilizing FACS. 1147 Isolated transfected cells are sparsely seeded and expanded for subsequent growth of single 1148 cell-derived colonies. Appropriate means for analyses allow for the selection of a favored 1149 colony, which is then established as cell line. 1150

1151

1152

Figure 5 Transfection efficacy and cell viability applying various transfection methods using vectors of different size and diverse cell lines

The efficacy of iPS cells transfected with a vector was compared using a small guide-only (4 1155 kb) and a large combined plasmid (12 kb) applying three methods: Gene Pulser Xcell, Neon 1156 Transfection System and Lipofectamine 3000. By Gene Pulser Xcell 20 µg of DNA were 1157 transfected, 5 µg by Neon System and 1.5 µg by Lipofectamine 3000. Efficacy was assessed 1158 by FACS analysis, counting positively transfected single cells detected by a fluorescent 1159 reporter included in the vector. 5x10⁵ cells were subjected to Gene Pulser Xcell and Neon 1160 Transfection System of which 1x10⁵ were subsequently cultured. 1x10⁵ cells were subjected 1161 to Lipofectamine 3000 transfection. Viability was determined after 48h by FACS based 1162 1163 quantification of remaining single cells. A Cells of the BCRT#1 iPS cell line were transfected at differing efficacy when subjected to Gene Pulser Xcell, Neon Transfection System and 1164

Lipofectamine 3000. Transfection efficacy delivering the small guide-only vector amounts to 1165 41% of all FACS identified single cells using Gene Pulser Xcell, 65% with the Neon System 1166 1167 and 82% after Lipofectamine 3000 transfection. Delivering the large combined vector yields a 1168 decreased efficacy regardless the method used. Transfection by Gene Pulser Xcell results in 1169 10% of successfully transfected single cells, by Neon Transfection System 27% and applying Lipofectamine 3000 achieve 59%. B Viability of transfected BCRT#1 iPS cells varies 1170 1171 depending on the transfection method used as well as on the size of the vector delivered. 1172 After transfection of the 4 kb vector by Gene Pulser Xcell, Neon System and Lipofectamine 3000, 6900, 5400 and 6800 remaining single cells were detected, respectively. Subjecting 1173 1174 the 12 kb vector to transfection yielded 4000, 400 and 2500 live cells. C Efficacy of 1175 transfecting a 4 kb vector varied between the hiPS cell lines BCRT#1, XM001 and MIRJT7imND2-0. Treatment with Gene Pulser Xcell resulted in 41%, 50% and 25% efficacy, with 1176 Neon Transfection System 65%, 90% and 38%, with Lipofectamine 3000 82%, 96% and 1177 1178 90%, respectively. **D** Cell viability was evaluated after applying different transfection methods 1179 to BCRT#1, XM001 and MIRJT7i-mND2-0 iPS cell lines. After transfection by Gene Pulser Xcell 6800, 5800 and 4200 live cells of the respective cell lines were detected, after Neon 1180 Transfection System application 5400, 5700 and 2600 remaining single cells were quantified, 1181 and after Lipofectamine 3000, 6900, 5100 and 100 cells. Experiments were performed in 1182 triplicates; error bars represent standard error of the mean; significance as per Student's t-1183 test: *<0.05, **<0.005, ***<0.0005, n.s.=not significant. 1184

- 1185
- 1186

1187

1188Figure 6 Scheme of the enrichment of hiPS cells transfected for CRISPR/Cas9-1189mediated gene editing

A After transfection of hiPS cells with an appropriate reporter expressing vector, transfected cells are identified by FACS based on their fluorescent signal. To increase the yield of successfully targeted cells, isolated cells can be expanded and resubjected to transfection and FACS enrichment. Representative image of a FACS plot. **B1** Single FACS-isolated transfected hiPS cells are cultivated sparsely. **B2-B5** During the next 5 days following seeding a small colony arises from a single cell. **B6** After 5 days of culturing a colony forms large enough for manual picking and further expansion. Scale bar represents 100 μm.

1197

1198

Figure 7 Targeted hiPSCs express pluripotency markers and can differentiate to the ectodermal lineage

1202 A Edited hiPS cells (BCRT#1; edited) and the parental cell line (BCRT#1; parental) were subjected to immuno-cytochemistry using antibodies against the pluripotency markers 1203 SSEA4 (NEB #4755S; 1:500) and NANOG (NEB #4903S; 1:500), OCT4 (NEB #2750S; 1204 1:500) or SOX2 (NEB #3579S; 1:500), respectively. Nuclei were visualized by DAPI. The 1205 edited cell line was targeted in two successive steps. Firstly, the AAVS1 locus was targeted 1206 1207 to express doxycycline inducible Cas9. Subsequently, three native loci were biallelically mutated following Workflow B, including two rounds of transfection (and co-transfection of 1208 Trex2) and FACS enrichment. B The edited cell line (BCRT#1; edited) and a control cell line 1209 1210 which was targeted at the AAVS1 locus to express Cas9 under a doxycycline inducible 1211 promotor (BCRT#1; control) were differentiated using the Dopaminergic Neuron 1212 Differentiation Kit (Thermo Fisher Scientific) according to the manufacturer's protocol. At Day 1213 38 cells were fixed and subjected to immuno-cytochemistry for the pan-neuronal marker TUJ1 (BioLegend #801202; 1:1000) and the dopaminergic neuronal marker TH (Pel-Freez 1214 #P40101; 1:1000). Nuclei were visualized by DAPI. A and B Cells were cultivated on glass 1215 cover slips coated with VTN-T (A) or Laminin/Poly-D-Lysin (B). Prior to staining cells were 1216 fixed for 7 min at RT with 4 % PFA in PBS. Cells were washed thrice with PBS and 1217 subsequently permeabilized and blocked for 30 min at RT with PBS containing 3 % BSA and 1218 0.2 % TritonX-100. The cells were washed three more times with PBS and incubated with the 1219 respective primary antibodies O/N at 4 °C. The next day, cells were again washed thrice 1220 1221 with PBS and incubated for 1 h at RT with secondary antibodies (goat-anti rabbit-AF488 and goat anti-mouse-AF546, both Thermo Fisher Scientific) and DAPI in PBS supplemented with 1222 3 % BSA. After final three washes in PBS cells were mounted on glass slides with 1223 Fluoromount-G (SouthernBiotech). Imaging was performed on a LSM700 confocal 1224 1225 microscope (Zeiss) with a 20x objective.

1226

1227

1228

1229

1230

1231


1233 References


- 1234
 1235 [1] K. Takahashi, S. Yamanaka, Induced pluripotent stem cells in medicine and biology,
 1236 Development. 140 (2013) 2457–2461. doi:10.1242/dev.092551.
- 1237 [2] J.L. Sterneckert, P. Reinhardt, H.R. Scholer, Investigating human disease using stem 1238 cell models, Nat Rev Genet. 15 (2014) 625–639. doi:10.1038/nrg3764.
- 1239 [3] K. Takahashi, S. Yamanaka, A decade of transcription factor-mediated reprogramming 1240 to pluripotency, Nat. Rev. Mol. Cell Biol. 17 (2016) 183–193. doi:10.1038/nrm.2016.8.
- 1241[4]Y. Tao, S.-C. Zhang, Neural Subtype Specification from Human Pluripotent Stem1242Cells, Cell Stem Cell. 19 (2016) 573–586. doi:10.1016/j.stem.2016.10.015.
- 1243[5]S.G. Priori, C. Napolitano, E. Di Pasquale, G. Condorelli, Induced pluripotent stem1244cell-derived cardiomyocytes in studies of inherited arrhythmias, J. Clin. Invest. 1231245(2013) 84–91. doi:10.1172/JCI62838.
- 1246 [6] D. Hockemeyer, R. Jaenisch, Induced Pluripotent Stem Cells Meet Genome Editing, 1247 Cell Stem Cell. 18 (2016) 573–586. doi:10.1016/j.stem.2016.04.013.
- A. Hotta, S. Yamanaka, From Genomics to Gene Therapy: Induced Pluripotent Stem
 Cells Meet Genome Editing, Annu. Rev. Genet. 49 (2015) 47–70.
 doi:10.1146/annurev-genet-112414-054926.
- 1251 [8] O. Zuk, E. Hechter, S.R. Sunyaev, E.S. Lander, The mystery of missing heritability:
 1252 Genetic interactions create phantom heritability, Proc. Natl. Acad. Sci. 109 (2012)
 1253 1193–1198. doi:10.1073/pnas.1119675109.
- 1254 [9] B. Lehner, Molecular mechanisms of epistasis within and between genes, Trends 1255 Genet. 27 (2011) 323–331. doi:10.1016/j.tig.2011.05.007.
- 1256 [10] S.H. Sternberg, J.A. Doudna, Expanding the Biologist's Toolkit with CRISPR-Cas9, 1257 Mol. Cell. 58 (2015) 568–574. doi:10.1016/j.molcel.2015.02.032.
- [11] Q. Ding, S.N. Regan, Y. Xia, L.A. Oostrom, C.A. Cowan, K. Musunuru, Enhanced
 Efficiency of Human Pluripotent Stem Cell Genome Editing through Replacing
 TALENs with CRISPRs, Cell Stem Cell. 12 (2013) 393–394.
 doi:10.1016/j.stem.2013.03.006.
- 1262 [12] H.S. Kim, J.M. Bernitz, D.-F. Lee, I.R. Lemischka, Genomic Editing Tools to Model
 1263 Human Diseases with Isogenic Pluripotent Stem Cells, Stem Cells Dev. 23 (2014)
 1264 2673–2686. doi:10.1089/scd.2014.0167.
- 1265 [13] W.T. Hendriks, C.R. Warren, C.A. Cowan, Genome Editing in Human Pluripotent Stem
 1266 Cells: Approaches, Pitfalls, and Solutions, Cell Stem Cell. 18 (2016) 53–65.
 1267 doi:10.1016/j.stem.2015.12.002.
- 1268 [14] F.A. Ran, P.P.D. Hsu, J. Wright, V. Agarwala, D. a Scott, F. Zhang, Genome engineering using the CRISPR-Cas9 system., Nat. Protoc. 8 (2013) 2281–308. doi:10.1038/nprot.2013.143.
- 1271 [15] M.R. Lieber, The Mechanism of Double-Strand DNA Break Repair by the

- Nonhomologous DNA End-Joining Pathway, Annu. Rev. Biochem. 79 (2010) 181–211.
 doi:10.1146/annurev.biochem.052308.093131.
- 1274 [16] J. San Filippo, P. Sung, H. Klein, Mechanism of Eukaryotic Homologous
 1275 Recombination, Annu. Rev. Biochem. 77 (2008) 229–257.
 1276 doi:10.1146/annurev.biochem.77.061306.125255.
- 1277 [17] W.-D. Heyer, K.T. Ehmsen, J. Liu, Regulation of Homologous Recombination in
 1278 Eukaryotes, Annu. Rev. Genet. 44 (2010) 113–139. doi:10.1146/annurev-genet 1279 051710-150955.
- [18] D.A. Sorrell, A.F. Kolb, Targeted modification of mammalian genomes, Biotechnol.
 Adv. 23 (2005) 431–469. doi:10.1016/j.biotechadv.2005.03.003.
- F. González, Z. Zhu, Z.D. Shi, K. Lelli, N. Verma, Q. V. Li, D. Huangfu, An iCRISPR
 platform for rapid, multiplexable, and inducible genome editing in human pluripotent
 stem cells, Cell Stem Cell. 15 (2014) 215–226. doi:10.1016/j.stem.2014.05.018.
- [20] C.-Y. Park, J. Kim, J. Kweon, J.S. Son, J.S. Lee, J.-E. Yoo, S.-R. Cho, J.-H. Kim, J.-S.
 Kim, D.-W. Kim, Targeted inversion and reversion of the blood coagulation factor 8
 gene in human iPS cells using TALENs, Proc. Natl. Acad. Sci. 111 (2014) 9253–9258.
 doi:10.1073/pnas.1323941111.
- S. Turan, A.P. Farruggio, W. Srifa, J.W. Day, M.P. Calos, Precise Correction of
 Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb
 Girdle Muscular Dystrophy, Mol. Ther. 24 (2016) 685–696. doi:10.1038/mt.2016.40.
- [22] L. Ye, J. Wang, A.I. Beyer, F. Teque, T.J. Cradick, Z. Qi, J.C. Chang, G. Bao, M.O.
 Muench, J. Yu, J.A. Levy, Y.W. Kan, Seamless modification of wild-type induced
 pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV
 infection, Proc. Natl. Acad. Sci. 111 (2014) 9591–9596.
 doi:10.1073/pnas.1407473111.
- 1297 [23] F.T. Merkle, W.M. Neuhausser, D. Santos, E. Valen, J.A. Gagnon, K. Maas, J.
 1298 Sandoe, A.F. Schier, K. Eggan, Efficient CRISPR-Cas9-Mediated Generation of
 1299 Knockin Human Pluripotent Stem Cells Lacking Undesired Mutations at the Targeted
 1300 Locus, Cell Rep. 11 (2015) 875–883. doi:10.1016/j.celrep.2015.04.007.
- 1301 [24] D. Paquet, D. Kwart, A. Chen, A. Sproul, S. Jacob, S. Teo, K.M. Olsen, A. Gregg, S.
 1302 Noggle, M. Tessier-Lavigne, Efficient introduction of specific homozygous and 1303 heterozygous mutations using CRISPR/Cas9, Nature. 533 (2016) 125–129.
 1304 doi:10.1038/nature17664.
- 1305 [25] J.W. Shin, K.-H. Kim, M.J. Chao, R.S. Atwal, T. Gillis, M.E. MacDonald, J.F. Gusella,
 1306 J.-M. Lee, Permanent inactivation of Huntington's disease mutation by personalized
 1307 allele-specific CRISPR/Cas9., Hum. Mol. Genet. (2016) ddw286.
 1308 doi:10.1093/hmg/ddw286.
- 1309 [26] S.Q. Tsai, J.K. Joung, Defining and improving the genome-wide specificities of 1310 CRISPR–Cas9 nucleases, Nat. Rev. Genet. 17 (2016) 300–312.
 1311 doi:10.1038/nrg.2016.28.
- 1312 [27] A. Veres, B.S. Gosis, Q. Ding, R. Collins, A. Ragavendran, H. Brand, S. Erdin, C.A.
 1313 Cowan, M.E. Talkowski, K. Musunuru, Low Incidence of Off-Target Mutations in
 1314 Individual CRISPR-Cas9 and TALEN Targeted Human Stem Cell Clones Detected by


- 1315 Whole-Genome Sequencing, Cell Stem Cell. 15 (2014) 27–30.
 1316 doi:10.1016/j.stem.2014.04.020.
- 1317 [28] K. Suzuki, C. Yu, J. Qu, M. Li, X. Yao, T. Yuan, A. Goebl, S. Tang, R. Ren, E. Aizawa,
 1318 F. Zhang, X. Xu, R.D. Soligalla, F. Chen, J. Kim, N.Y. Kim, H.-K. Liao, C. Benner, C.R.
 1319 Esteban, Y. Jin, G.-H. Liu, Y. Li, J.C. Izpisua Belmonte, Targeted Gene Correction
 1320 Minimally Impacts Whole-Genome Mutational Load in Human-Disease-Specific
 1321 Induced Pluripotent Stem Cell Clones, Cell Stem Cell. 15 (2014) 31–36.
 1322 doi:10.1016/j.stem.2014.06.016.
- [29] L. Yang, D. Grishin, G. Wang, J. Aach, C.-Z. Zhang, R. Chari, J. Homsy, X. Cai, Y.
 Zhao, J.-B. Fan, C. Seidman, J. Seidman, W. Pu, G. Church, Targeted and genomewide sequencing reveal single nucleotide variations impacting specificity of Cas9 in
 human stem cells, Nat. Commun. 5 (2014) 5507. doi:10.1038/ncomms6507.
- 1327 [30] I.M. Slaymaker, L. Gao, B. Zetsche, D.A. Scott, W.X. Yan, F. Zhang, Rationally
 1328 engineered Cas9 nucleases with improved specificity, Science (80-.). 351 (2016) 84–
 1329 88. doi:10.1126/science.aad5227.
- [31] B.P. Kleinstiver, V. Pattanayak, M.S. Prew, S.Q. Tsai, N.T. Nguyen, Z. Zheng, J. Keith
 Joung, High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off target effects, Nature. 529 (2016) 490–495. doi:10.1038/nature16526.
- 1333 [32] I. Streeter, P.W. Harrison, A. Faulconbridge, P. Flicek, H. Parkinson, L. Clarke, The human-induced pluripotent stem cell initiative—data resources for cellular genetics, Nucleic Acids Res. 45 (2017) D691–D697. doi:10.1093/nar/gkw928.
- 1336[33]L. Xi, J.C. Schmidt, A.J. Zaug, D.R. Ascarrunz, T.R. Cech, A novel two-step genome1337editing strategy with CRISPR-Cas9 provides new insights into telomerase action and1338TERT gene expression, Genome Biol. 16 (2015) 231. doi:10.1186/s13059-015-0791-13391.
- 1340 [34] J.A. Schick, C. Seisenberger, J. Beig, A. Bürger, V. Iyer, V. Maier, S. Perera, B.
 1341 Rosen, W.C. Skarnes, W. Wurst, CRISPR-Cas9 enables conditional mutagenesis of
 1342 challenging loci, Sci. Rep. 6 (2016) 32326. doi:10.1038/srep32326.
- Y. Miyaoka, A.H. Chan, L.M. Judge, J. Yoo, M. Huang, T.D. Nguyen, P.P. Lizarraga,
 P.-L. So, B.R. Conklin, Isolation of single-base genome-edited human iPS cells
 without antibiotic selection, Nat. Methods. 11 (2014) 291–293.
 doi:10.1038/nmeth.2840.
- 1347 [36] S. Makino, R. Fukumura, Y. Gondo, Illegitimate translation causes unexpected gene
 1348 expression from on-target out-of-frame alleles created by CRISPR-Cas9, Sci. Rep. 6
 1349 (2016) 39608. doi:10.1038/srep39608.
- 1350 [37] A.G. Pedersen, H. Nielsen, Neural network prediction of translation initiation sites in
 1351 eukaryotes: perspectives for EST and genome analysis., Proceedings. Int. Conf. Intell.
 1352 Syst. Mol. Biol. 5 (1997) 226–33.
- 1353 [38] C.-Y. Park, J.J. Sung, S.-H. Choi, D.R. Lee, I.-H. Park, D.-W. Kim, Modeling and
 1354 correction of structural variations in patient-derived iPSCs using CRISPR/Cas9, Nat.
 1355 Protoc. 11 (2016) 2154–2169. doi:10.1038/nprot.2016.129.
- 1356 [39] K. Kraft, S. Geuer, A.J. Will, W.L. Chan, C. Paliou, M. Borschiwer, I. Harabula, L.
 1357 Wittler, M. Franke, D.M. Ibrahim, B.K. Kragesteen, M. Spielmann, S. Mundlos, D.G.

- Lupiáñez, G. Andrey, Deletions, Inversions, Duplications: Engineering of Structural
 Variants using CRISPR/Cas in Mice, Cell Rep. 10 (2015) 833–839.
 doi:10.1016/j.celrep.2015.01.016.
- [40] M. Haeussler, K. Schönig, H. Eckert, A. Eschstruth, J. Mianné, J.-B. Renaud, S.
 Schneider-Maunoury, A. Shkumatava, L. Teboul, J. Kent, J.-S. Joly, J.-P. Concordet,
 Evaluation of off-target and on-target scoring algorithms and integration into the guide
 RNA selection tool CRISPOR, Genome Biol. 17 (2016) 148. doi:10.1186/s13059-0161012-2.
- [41] L. Yang, M. Guell, S. Byrne, J.L. Yang, A. De Los Angeles, P. Mali, J. Aach, C. KimKiselak, A.W. Briggs, X. Rios, P.Y. Huang, G. Daley, G. Church, Optimization of
 scarless human stem cell genome editing, Nucleic Acids Res. 41 (2013) 9049–9061.
 doi:10.1093/nar/gkt555.
- 1370 [42] C.D. Richardson, G.J. Ray, M.A. DeWitt, G.L. Curie, J.E. Corn, Enhancing homology1371 directed genome editing by catalytically active and inactive CRISPR-Cas9 using
 1372 asymmetric donor DNA, Nat. Biotechnol. 34 (2016) 339–344. doi:10.1038/nbt.3481.
- I373 [43] J.B. Renaud, C. Boix, M. Charpentier, A. De Cian, J. Cochennec, E. DuvernoisBerthet, L. Perrouault, L. Tesson, J. Edouard, R. Thinard, Y. Cherifi, S. Menoret, S.
 Fontanière, N. de Crozé, A. Fraichard, F. Sohm, I. Anegon, J.P. Concordet, C.
 Giovannangeli, Improved Genome Editing Efficiency and Flexibility Using Modified
 Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases, Cell Rep. 14 (2016)
 2263–2272. doi:10.1016/j.celrep.2016.02.018.
- 1379[44]A. Glaser, B. McColl, J. Vadolas, GFP to BFP Conversion: A Versatile Assay for the1380Quantification of CRISPR/Cas9-mediated Genome Editing, Mol. Ther. Acids. 5 (2016)1381e334. doi:10.1038/mtna.2016.48.
- P. Hasty, A. Abuin, A. Bradley, Gene targeting, principles, and practice in mammalian cells, in: A. Joyner (Ed.), Gene Target. A Pract. Approach, Second Edi, Oxford University Press, Oxford, 2000: pp. 1–35.
- 1385 [46] B. Wefers, W. Wurst, R. Kühn, Design and Generation of Gene-Targeting Vectors, in:
 1386 Curr. Protoc. Mouse Biol., John Wiley & Sons, Inc., Hoboken, NJ, USA, 2011: pp.
 1387 199–211. doi:10.1002/9780470942390.mo100179.
- 1388 [47] Derek Peters; Chad Cowan; Kiran Musunuru, Genome editing in human pluripotent 1389 stem cells, in: StemBook, Cambridge, 2014. doi:10.3824/stembook.1.94.1.
- 1390[48]E.K. Brinkman, T. Chen, M. Amendola, B. van Steensel, Easy quantitative assessment1391of genome editing by sequence trace decomposition, Nucleic Acids Res. 42 (2014)1392e168–e168. doi:10.1093/nar/gku936.
- 1393
- 1394
- 1395
- 1396
- 1397
- 1398






1409 Figure 2




1410 1411


1412 Figure 3

BCRT#1-AAVS1 EGFP/+ CAG-Cas9-U6sgRNA(EGFP)-EF1-TagRFP soDN donor template






1421 Figure 4




```
1423 Figure 5
```



- 4 4 2 2





1436 Figure 7

